b e h r n g e r n g e l h e value innovationc n e n partn ers hip collaboration external partner play important role boehringer ingelheim research development strategy enquire indep end ence innovation mean familyowned company boehringer ingelheim able support basic innovation research lead new medicine breakthrough diabete research long term inspiration boehringer ingelheim convince broad horizon freedom think bring good idea innovate venture capital innovative idea discover new thing boehringer ingelheim commit ment research development zebrafish news sust aina bility concept prove worth space free creative thinking boehringer ingelheim take responsibility environment say generate great efficiency innovative imprint see different eye product help management need inspire team improve sustainably reduce ecological footprintvalue innovation innovation time fundamental requirement driving force boehringer ingelheim researchdriven pharmaceutical company world employee work day day develop novel efficacious medicine people animal field human pharmaceutical boehringer ingelheim portfolio contain example compound treatment respiratory disease cardiovascular disease disease central ner vous system metabolic infectious disease cancer net sale billion euro boehringer ingelheim world lead pharmaceutical company found company remain familyowned day social responsibility important element corporate culture boehringer ingelheim include worldwide involvement social project example initiative make health care employee respect equal opportunity reconc ile career family form foundation mutual cooperation company focus environmental protec tion sustainability enquire boehringer ingelheim w h n n v n e n u innovation important motivating force boehringer ingelheim researchdriven pharmaceutical company ask chairman shareholders committee board manage director innovation mean personally innovation easy grasp successful research new edicine christian boehringer chairman shareholders committee innovation boehringer ingelheim easy grasp successful research new medicine begin establishment scientific department give environment time shortly world war launch respiratory medication lobelin remarkable appreciate familyowne company well grow organically independently successful research development today firmly anchor shareholder cor porate understand innovation swine vaccine ingelvac circoflex pradaxa stroke prevention atrial fibrillation late datum empareg outcome study highrisk patient type diabetes example commitment enquire boehringer ingelheim thing well simple differently resource value innovation apply function organisation professor andreas barner chairman board manage director dr wolfgang baiker innovation boehringer ingelheim member board manage director responsibility biopharmaceutical operation thing well simple differently resource well mean new therapeutic option well simple intelligent computer pro gramme shorten routine task innovation benefit key stakeholder thing completely different add value internal external boehringer ingelheim understand complex science question innovation simply thing differently invent early stage easily prevent thing new value obvious see somebody frown strict selection process innovation pharmaceutical company like idea lead well idea course new treatment paradigm treatment careful one strive foster climate idiopathic pulmonary fibrosis ipf patient ofev innovation flourish intelligently efficiently benefit environment example emit carbondioxide concept value innovation apply function organisation contribute share innovation enquire boehringer ingelheim make change friend enemy dr joachim hasenmai member board manage director responsibility animal health consumer health care chc remain young company world con mind building stant change commitment value experience innovation mean make change friend enemy value inno vation go way product innovation innovation culture hubertus von baumbach strategy product portfolio process member board manage director behaviour attitude personal development responsibility finance innovation product mean add value customer imply define innovation eye time innovation way thing mean competitiveness rapidly change environment constant improve ment innovation essentially remain young mind building experience enquire boehringer ingelheim positively impact health world allan hillgrove member board manage director responsibility pharma marketing sale innovation breakthrough add significant value come form example product technology way operate example brilliant diverse innovation boehringer ingelheim recent mind work benefit diabetes compound empagli flozin prove trial cardiovascular goal death reduce cent clear external benefit show innovation bring health benefit society eg dr andreas neumann product prevent death reduce time patient spend hospital gratifying member board manage director company positively impact responsibility human resource health world innovation key driver company success today tomorrow directly link brilliant diverse mind work goal people perspective truly believe diversity inclusion unlock innovation drive market growth want lever age global power boehringer ingelheim diversity foster environment outsidethebox thinking encourage employee propose novel idea leader give diverse voice airtime space unleash innov ative potential researchdriven pharmaceutical company innovation boehringer ingelheim b r e k h r u g h n abe e r e e r c h boehringer ingelheim innovation primarily mean able help people new effective medicine example empareg outcome trial patient type diabete show compound discover developed boehringer ingelheim prevent death c ardiovascular complication diagnosis type diabetes come shock large advice control blood sugar patient aware condi need quit smoking need start exercise tion frequently doctor tell people helpful patient diabete lead death fact step time start change diet world die diabete seven second smoking begin exercise life expectancy people diabete reduce adjust healthy lifestyle sufficient year cardiovascular disease people diabetes begin treatment half people diabete medicine addition lower blood sugar real healthy living habit good way prevent heart dis goal prevent longterm complication especially cardio ease stroke patient overwhelm vascular increase life expectancy innovation boehringer ingelheim recent ray hope people diabete high risk cardiovascular disease empareg outcome trial major international study patient show medication treat type diabetes pre vent death patient high risk cardiovascular event medication result cent reduce people risk allcause mortality cent reduce risk hospitalisation heart failure result achieve work boehringer ingelheim research standard care development innovative medicine midseptember boehringer ingelheim eli lilly company present result empareg outcome study st european association study diabete annual meeting stockholm expert react spontaneous applause recall professor hansjrgen wrle global vice president medicine boehringer ingelheim study medica billion euro tion treatment diabete lower death rate cardiovascular event video patient type diabete talk experience visit httpbitlyya research development zinman b et al empagliflozin cardiovascular outcome expenditure mortality type diabete n engl j med innovation therapeutic area boehringer ingelheim successful breakthrough diabete research pharmaceutical company successfully develop innovative medication patient study therapeutic area respiratory disease new therapeutic option patient suffer rare devastating disease idiopathic pulmo nary fibrosis ipf respiratory disease ii maintenance treatment currently progress boehringer ingelheim chronic obstructive pulmonary disease copd introduce status december new maintenance product relieve symptom adult patient cardiology specific reversal agent rapidly reverse effect oral anticoagulant dabigatran emergency situa tion important surgery require oncology treatment advanced nonsmall cell lung cancer boehringer ingelheim compound inhibit patient growth new blood vessel withhold nutrient tumour require grow expand study currently progress overall recruit status december n n v tio n n e e spir ion inspiration boehringer ingelheim se e n g h r u g h f f e r e not e e getting know people culture enrich work new perspective boehringer ingelheim convince broad horizon freedom think bring good idea bright red chilli gleam afternoon sun market glance sign poverty hardship disease tamil nadu southern india heat oppressive instead abundance freshly pick fruit vege air dusty trader improvise wooden table barrow table price equivalent euro cent real bargain sag weight heavily laden basket corn european employee boehringer ingelheim herb spice brightness fruit vegetable wander south indian market april compete colourful saris customer carefully far cry supermarket price pay check item fresh quality home right lively bartering price begin inspiration boehringer ingelheim leadership training instill set value future culture company want promote innovative thinking order improve access healthcare people today access difficulty manuela pastore manager boehringer ingelheim initiative make heal th november second group boehringer ingelheim manager take insight week india inspiration boehringer ingelheim frank kornely team leader cardiovascular marketing boehringer ingelheim germany initially hope insight trip help learn busi ness work region make country people tick happen journey truly view market today exposure trip expose new spective western tourist people earn average thing new experience unlike tradi indian wage indian rupee euro tional seminar coaching not cent disposal people live learn load fact market par region spend food day ticular method solve problem market money quickly realise learn close look thing impossible buy good food say manuela question way think work pastore manager boehringer ingelheim initiative daytoday work make health mmh set organise standard grant business leadership programme trip southern india colleague world rule private life take trip spend week familiarising conduct completely daytoday life local get different standard today picture local mmh initiative project open flexible approach working boehringer ingelheim promote innovative project support standard actually healthcare ward budget manage team experience go make health project week india daily life work participant head want personal contribution difference individ image impression ual skill ability standardise solution idea apply board simply brake motivation contribute inspiration boehringer ingelheim sabine nikolaus change head prescription medicine country perspective regional centre vienna boehringer ingelheim inspire austria make health project india impress social entrepreneur project achieve simple mean fascinate approach talk people exam ine situation closely want understand need develop solution solution bring improvement people perspec tive consider improve ment western viewpoint convince important innovation trends field healthcare emerge social area travel lot daytoday work experience different country culture work diverse range company department week india focus attention complexity diversity different country market environment way improve people health particular environment regard experience important suade country manager team insight week insight week participant opportunity talk people hospital primary healthcare clinic inspiration boehringer ingelheim krystian fikert mmh fellow founder ceo mymind centre mental wellbeing ireland mmh fellow take insight trip find health care project india exchange idea fellow base high sui cide rate india psychological problem arise deeproote caste system shock work make health support centre mental health india strengthen selfconfidence people local community invaluable work create well mental health homeless community visit new nursery set rural region social enterprise mymind pur mmh fund important point sue similar approach ireland contact local healthcare issue speak people mental health everyone reach hospital basic healthcare clinic find care support accessible welltraine medical staff observe lack affordable need insight resource give rise creative pragmatic solution week give lot idea dynamic idea social entrepreneur use model help people develop experience bureaucratic develop country india cultural obstacle lack knowledge prevent develop idea people seek medical care simple problem benefit india see firsthand european standard complex prac high level poverty mental health tice problem plague community week india participant head thought mymind provide image impression idea say manuela pastore early intervention service deal high inspiration stay long time accompany level suicide student young people live realise develop country inspiration boehringer ingelheim patrick buckley head sale executive manager ireland boehringer ingelheim uk expect arrive poverty stricken country quickly que tion view people meet show participant second happiness dependent insight week hello child children home material thing definition poverty learn question way solve problem ascertain example relatively straightforward improve health lot child implement simple hygiene rule think teach par ent rule simple solution daytoday work lead question glance change people process routine team previously take routine cultural attitude long give daily professional life participant term mmhsupporte ashoka fellow insight india trip successful hardworking manager head come idea regional team expert medical field develop marketing effective child soap campaign manage sale key european market glance school project daytoday work common daily life parent present people india mmh project precisely change child know parent proud perspective break entrench daily routine value gift want child think pattern inspire week month pleasure see use trip participant get touch ve experience broaden come idea make health programme horizon remind important want recommend young leader insight open mind approach week india successfully try innovative usual solution attitude approach team daily work inspiration boehringer ingelheim l p n g e c h oth e r deeplyembedde boehringer ingelheim corporate culture help people learn appreciate difference culture language particularly important boehringer ingelheim international company people nation work corporate headquarters ingelheim germany great sympathy company everyday live large number refugee germany come surprise empathy respect fundamental pillar cor porate culture boehringer ingelheim say stefan rinn country man ager germany s attitude people come refugee treat empathy respect learn boehringer ingelheim event cooking friend instance refugee family migrant sponsor company prepare food know contact evolve friendship company workshop state institution asylum seeker deportee ingelheim example refugee learn germany give opportunity find strange country learn inspiration boehringer ingelheim volunteer patient seek doctor nurse nurse practitioner employee boehringer ingelheim ridgefield site usa respond appeal donate time skill serve patient health insurance register nurse tricia keller volunteer boehringer ingelheim americare free clinic neighbouring danbury uninsured patient year receive medical help past year boehringer ingelheim care foundation donate million dollar improve clinic enable help patient support boehringer ingelheim go far financial commitment employee volunteer spanish portuguese interpret er help patient speak provider volunteer ing give opportunity help patient life different perspective say tricia truly enrich life happy foot get fresh air good source inspiration people bring movement employee live boehringer ingelheim set happy foot campaign china month employee encourage journey work foot start campaign company organise walking challenge day boehringer ingelheim employee clock kilometer correspond width china west east boehringer ingelheim convert distance money able donate yuan euros childrens hospital shanghai inspiration boehringer ingelheim n g eme not n e e boehringer ingelheim make health n p r e th e r te am make health mmh shawn liu initiative employee boehringer ingelheim global hr strategy tran year support inspire innovation formation lead global improve healthcare world head leadership develop ment commitment participant new experience order help make health insight open mind require india week trip inspire ment increasingly complex personally fast move global economy inspire foremost sight programme make important impressive people contribution management boehringer ingelheim employee fortunate meet people run operate environment com involve mmh initiative ngos hospital manager selfhelp pletely new learn group manager manage ngo social entrepreneur lead inspiration difficult demand project team passion motivation modesty passion order m condition great prove people quality life uncertainty partly enormous project succeed natu pressure limited resource rally employ mean available people leader experience important ship accomplish guide management share value pursue clear success future de healthcare innovation goal learn lot player pend management staff social sector idea position deal innovatively support partnership leadership style manent change completely new environment diverse range make health player recognise sight programme fix promote good idea matter global leadership develop come innovation occur ment programme boehringer ingel motivate people heim management inspire team exposure important compo allow inspire nent management development new experience impression time global idea competition management face n n v tio n n e e ner ship partn er hip boehringer ingelheim n v n g g e h e r paola casarosa start work boehringer ingelheim laboratory today look external partner field prescription medicine involve cast wide net world know important partnership biotech startup develop innovation partn er hip boehringer ingelheim pave way external partnership helping ensure pipeline wellstocke new medicine boston world biotech hotspot dr paola casarosa talk meeting tant present person meet right startup academic institution boston people say strategy prescription quickly passionate biotech medicine substantial external component scene oneofakind m dr casarosa come turin italy m fascinate rapidly biomedical sci graduate medical chemistry com ence evolve new biotechs venture plete doctorate molecular pharmacology investor time people netherlands hold post excite entrepreneurial atmosphere pharmaceutical company move breathe say boehringer ingelheim initially work corporate vice president busi research join business develop ness development licensingprescription ment team year medicine boehringer ingelheim visit work develop therapeutic alliance city east coast time year strategic partnership pave way strengthen boehringer ingelheim visibility external partnership helping ensure ner choice know potential new pipeline wellstocke new ner colleague permanent medicine fixture office boston impor partn er hip boehringer ingelheim work key interface com thomson reuter time name boehringer ingelheim pany boehringer ingelheim consistently build partner innovative company industry ship biotech recent year today cent search partnership drive ambition fill programme early middle stage boehringer therapeutic gap say dr casarosa work characterise ingelheim pipeline external innovation component scientific medical rationale pay biotech academia boehringer ingelheim wants invest partnership year company set spend billion euro cooperation external partner successful partnership partnership early stage boehringer ingelheim work successfully external partner research effective integrate innovative idea possible research development project example way create great benefit side oncology boehringer ingelheim conclude exclusive licensing agreement korean company hanmi pharma ceutical partner want work develop target dr casarosa regularly visit biotechnology hotspot therapy patient lung cancer display particular boston san francisco tokyo type mutation field cancer immunotherapy team hold partner day city past boehringer ingelheim work tbingenbased com year order facilitate dialogue promise pany curevac develop therapeutic tumour vaccine institution startup invitationonly event offer personal way engage innovator focus early clinical arena boehringer ingelheim recently oneonone interaction roundtable discussion seek exercise option acquire investigational drug open feedback establish future partner pharmaxis ltd treat progressive liver condition boehringer ingelheim partner approach specific need nonalcoholic steatohepatitis nash partnership early stage research effec tive way create great benefit side californian company circuit therapeutic underline dr casarosa help create right working boehringer ingelheim work optogenetic method identify relationship good position compound platform new therapy approach psychiatric cardiometabolic jointly shape development disease researchdriven pharmaceutical company boehringer ingelheim draw global network s important partner capability transform research finding successful new medicine help patient need say dr casarosa boehringer ingelheim track record product approval regulatory agency speak company gain new approval total new drug treat ment food drug administration fda european medicines agency ema good reason boehringer ingelheim rank innovative company idea pharma nominate year addition news agency partn er hip boehringer ingelheim n u r e c p l f r n n v v e e boehringer ingelheim venture fund equip million euro invest portfolio different biotech startup promise therapeutic idea accord dr frank kalkbrenner head venture fund boehringer ingelheim expressly look additional partnership partn er hip boehringer ingelheim boehringer ingelheim venture fund fact figure initial capital dr kalkbrenner kind company invest look young company research socalle scientific platform novel therapeutic concept new disease mechanism therapeutic modality potential application different indication area good example vaccine naturally primarily prevent infection act prophylactically million euro vaccine employ therapeutically tumour particular stimulate immune system attack tumour cell new scientific platform look outside holding startup therapeutic area boehringer ingelheim typically focus early stage eg financing e example company shareholder currently research development work topic like tissue regeneration treatment hearing loss clinical proof concept new therapeutic principle new therapeutic modality gene therapy treatment ophthalmologic disease boehringer ingelheim investment possible depend startup holding ear ground late development development biotech industry access knowledge knowhow framework therapeutic area founder biotech compa total investment ny benefit participation finance aspect true winwin partnership member supervisory board actively contribute development company build experience drug discovery development help shape strategy assist decision making addition network support search new partner additional investor need longterm partnership possible boehringer ingelheim investment highly innovative risky area like little smart bet project lead success near million euro company future assume boehringer ingelheim partner ship come venture fund portfolio optimal outcome venture capital equity investment colleague business development licensing paola casarosa tell look portfolio investment young mainly company exciting invention need speak technologyoriente company explore potential collaboration boehringer ingelheim promise simultaneously research development uncertain future partn er hip boehringer ingelheim c v e r n g n e w h n g g e h e r crowdsource cooperation public institution university boehringer ingelheim research development focus variety external partnership new approach explore external innovation crowdsourcing initiative academic bring good scientist groundbreake new approach attempt solve complex medical question example boehringer ingelheim initi ated crowdsourcing project unite interdisciplinary team boehringer ingelheim expand bilat expert world research new diseasemodifying eral partnership university approach treatment chronicobstructive pulmonary disease copd globally million people currently affect copd figure rise forecast predict disease bilateral partnership university major pillar world thirdbigg cause death boehringer ingelheim boehringer ingelheim approach research new therapy option finance research project year researcher ie new disease mechanism new therapeutic modality tech work biome x innovation center campus nologie new cooperation example university university heidelberg germany biome x take scientific request texas md anderson cancer center develop new medicine pharma company collect research proposal internet treatment pancreatic cancer account cent cancer applicant select good proposal build team researcher death worldwide effective medicine urgently need heidelberg facility working closely pharma scientist addition company conclude new partnership university group renowned institute icahn school medicine mount sinai massachusetts general hospital scripps research institute weill cornell medicine boehringer ingelheim explore company public institution microbiome eg gut microflora discover new approach research success treatment inflammatory bowel disease ibd crohns disease ulcerative colitis collaboration aim identify new medical research publicprivate partnership bring biomarker guide clinical study new therapeutic target good academic private researcher table jointly validate offer potential innovative medicine basic research precompetitive space partnership address significant unmet medical need ibd patient increasingly result major progress advantageous involve example open partnership company scientific institution include structural genomics consortium sgc innovative medicine initiative imi gprotein couple receptor gpcr consortium boehringer ingelheim play active role researchdriven pharmaceutical company university scientific institution partn er hip boehringer ingelheim boehringer ingelheim commitment research development billion euro billion euro billion euro assign preclinical research boehringer ingelheim invest invest partnership development rd include medicine year external partner innovation early middle research phase come external partnership n n v tio n ne e sus ta abi l m p r v n g u n b l brazil solana farm boehringer ingelheim take responsibility nature climate go say time generate great efficiency innovative product sus tain ability boehringer ingelheim adrian von treuenfels head solana farm brazil boehringer ingelheim cultivate medicinal plant little paradise start right field plant date year reforesta dozen bird fly dense treetops blue tion initial area hectare butterfly flutter coati trot cover young forest year refor tree bush shrub grow rampantly este area bind tonne co explain native forest surround cropland solana von treuenfels farm southern brazil planting tree phar plant human hand maceutical company main area business kilometres west paolo boehringer sustainability important topic ingelheim cultivate medicinal plant staff boehringer ingelheim antispasmodic precursor society company alike benefit medicine buscopan spiriva erosion extent solana farm instance medicinal make farming difficult result plant plant contour line provide decide mid reforest steep additional protection erosion pesticide slope go water say head subject strict criterion farm adrian von treuenfel employee col protect environment make land lecte seed seedling native forest nur fertile long term ecosystem remain ture sapling plant largely intact sus tain ability boehringer ingelheim native forest surround farmland solana farm provide habitat numerous animal coatis butterfly mid boehringer ingelheim decide partly refor area solana farm today matter course ask impact action sustainable say dr andreas gbler responsible boehringer ingelheim green initiative aim enable company reduce emission co equivalent cent euro revenue earn compare boehringer ingelheim make saving term energy resource innovation efficient environ mentally friendly product process sus tain ability boehringer ingelheim boehringer ingelheim take totally new path respimat picture assembly dortmund germany manufacturing respimat inhaler dortmund medicine powder form instead liquid boehringer facility germany case point way ingelheim pursue course handihaler common distant solana farm brazil pharmaceutical company switch powder thing respimat device enable people chronic inhaler device ideal lung disease inhale medicine spiriva fine patient able inhale deeply mist medicine enter small airway fine powder enter lung spiriva active substance come medicinal time decide completely plant solana farm new path explain dr joachim eicher senior expert respimat brazilian farm share respimat manufacturing department codevelope similarity term innovation protect climate inhaler nozzle boehringer ingelheim year ago montreal protocol come force respimat come market feature boehringer ingelheim management decide drastically spring force liquid medicine tiny little reduce chlorofluorocarbon cfc emission result nozzle mechanical pressure technique create damage ozone layer mean mist million micrometresize droplet well solution find standard pocket inhal technical milestone benefit global climate er day contain environ propellant standard device constitute g co mentally harmful propellant convert liquid medi equivalent inhaler cine store cartridge fine droplet good month save cent emission say alternative available time inhaler deliver dr eicher pride sus tain ability boehringer ingelheim mouthpiece uniblock dose chamber dose release button upper housing spring capillary tube clear base injection mould cartridge respimat plastic component boehringer ingelheim continually work office heat hotwater pipe sustainable small concrete ceiling project contribute reduce greenhouse progress exist gas importance building example ingelheim construction bi ingelheim boehringer site show pharmaceutical active substance ingelheim large administration building world building boehringer ingelheim switch wide design use little energy pos lighting system energysave technology sible heat exchanger recover heat extract cool system control room air summer ventilation system cool turn degree heat recovery space cool air result water optimise result building energy con evaporate effect airconditione system sumption decrease cent use additional electricity october respimat production facility receive environmental certification iso standard sus tain ability boehringer ingelheim dr gbler report boehringer ingelheim able decrease co emission big site cent relation energy consumption floor space ratio ie total floor space storey build ve come long way get well level say dr gbler company reward farsightedness new law come force brazil year ago short period time cent area own farm forest von treuenfel head solana farm new regulation problem thank reforestation project immediately fulfil quota boehringer ingelheim pay particular attention environmental aspect build bi large administrative building worldwide reduce eco boehringer ingelheim sustainability logical footprint sound basis boehringer ingelheim want sustainable reason professor andreas barner chairman board manage director sign responsible care global charter july concern com mitment chemical industry sustainability everyday corporate life example current initiative waste ridgefield facility usa boehringer ingelheim tries avoid waste possible remaining waste generate energy rest recycle possible proportion recycle waste increase cent cent result dangerous pharmaceuti cal waste end landfill reduce risk pollute soil groundwater clean fleet energy consumption airconditione heating system boehringer ingelheim facilities china japan set fix temperature airconditione system boehringer ingelheim headquar ter japan operate office hour thank change energy consumption significantly lower wastewater facility boehringer ingelheim operate modern water treatment plant ensure complete compliance legal limit example spanish malgrat de mar facility wastewater process biological step filter sand resource germany boehringer ingelheim introduce paper cent recycle fibre carry blue angel sustainability certification mkg reduction co emission relate energy consumption floor space ratio key facility boehringer ingelheim vehicle fleet germany trend co emission boehringer ingelheim company car mkg mkg sus tain ability boehringer ingelheim target electric vehicle n n v tio n ne e ep en dence z e b r f h n e w privately own pharmaceutical company boehringer ingelheim focus research development year company curiosity enable support basic research lead new medicine long term inde pen dence boehringer ingelheim toddler discover chance minute big sponsor sole shareholder signal peptide name toddler small size intervene project research field seemingly unsteady movement play major role currently scientist work study development zebrafish danio rerio basic molecular biology independent embryo miss heart develop institute remit conduct basic properly significance protein research high possible level zebrafish remain undiscovered decade pay period year imp mid study fish embryo author publish scientific complete scientist think article register patent imp discover know say researcher receive austria high dr andrea pauli scientist discover toddler endow research prize wittgenstein award dr pauli group leader boehringer ingelheim currently expand research institute molecular pathology imp commitment imp invest million vienna austria september boehringer euros construction new building fea ingelheim support basic research institute ture new spacious laboratory area important toddler zebrafish remain undiscovered decade inde pen dence boehringer ingelheim dr paulis innovative discovery possible independence basic researcher independence basic researcher dr paulis innova tive discovery possible freedom pursue sidetrack study eventually lead toddler researcher fact try track completely different mechanism toddler day find way basic research boehringer ingelheim biomedical laboratory toddler peptide cellular component form life include human actual function unknown similar peptide call apelin currently enjoy significant attention pharmaceutical research community great able discover basic research ultimately medicine help people imp researcher dr pauli saysinde pen dence boehringer ingelheim h e c n c e pt h p r v e n w rth inde pen dence boehringer ingelheim dr janmichael peters head research institute molecular pathology imp vienna austria interview explain pharmaceutical industry benefit independent basic research dr peters institute conduct basic research inno ogy pharmaceutical research concept prove vation need independence way scien worth think admirably farsighte strategy tist come new idea boehringer ingelheim work company dr janmichael peters yes convince privately own enable plan act long case possible break new ground want term pharmaceutical company explore new understand thing primary interest cure disease direction not imp inspire try want understand biological process actually func certain new idea tion cell division choose path not know advance journey ideal case pharmaceutical research lead new medicine innovative therapy time sound like unlimited intellectual freedom institute research contribute discovery exactly freedom extremely important johanne zuber physician molecular biologist able group leader search new possibility tar biological discovery way get cancer therapy approach find cancer cell attract good curiousitydriven scientist weak point serve possible target novel drug access kind people suspect able identify gene brd conduct contract research consider achille heel acute myeloid leukaemia particularly aggressive form blood cancer today allow research completely independently year discovery brd inhibitor expectation boehringer ingelheim basic clinical testing research high international level discover link practical application delight responsibility scientist human kind approach research team boehringer ingelheim tell discover interest found imp intend establish strong link molecular biol inde pen dence boehringer ingelheim space free creative thinking readiness keep family tradition preference leave acquire mean company fundamental significance future statement ernst boehringer young son company founder albert boehringer confirm belief tire safeguarding economic independence continue decisive importance success familyowne company entrepreneur humanisti cally incline world citizen see essential basis innovative ambition pharmaceutical research humanity life ernst boehringer demand promote safeguard valuable asset establish space employee pursue free creative thinking indispensable innovation constantly enable technical basis research development medicine high possible level good reason aware depend actually possible conviction important innovation thank independence independence thank anticipate thing innovation ernst boehringer work fight life late dr michael siebler ernst boehringer head boehringer ingelheim company archive courage thing independent researchdriven pharmaceutical company need lot capi founder boehringer ingelheim albert boehringer tal active substance pharmaceu attempt discover citric acid stumble tical medicine lot approach turn dead end thing entirely lactic acid boehringer courageous boehringer ingelheim shareholder family decision continue research suppose mistake reason shortterm investment build lactic acid industry constantly reinveste contrary independent up down profit research pave way company capital market shareholder great staying boehringer ingelheim know today power good example company history imprint boehringer ingelheim f u h ave n q u er es r c mm e nt p le e n h es tate c nta ct u boehringer ingelheim gmbh binger strae ingelheim germany telephone fax contact corporate division communication email webmasterboehringeringelheimcom internet wwwboehringeringelheimcom issue boehringer ingelheim gmbh concept design layout mpm corporate communication solution mainz wwwmpmde photo illustration rainer mirau p marion carniel p research institute molecular pathology p lennart nilsson p getty image p simone silbernagel mpm p fotolia p dieth schrder fotografie p julio vilela p thinkstock istockphoto p lukas beck p print neue sddeutsche verlagsdruckerei gmbh ulm copyright boehringer ingelheim gmbh right reserve annual report reproduce transmit form mean electronic photocopy permission write boehringer ingelheim gmbh figure party annual report base datum avail able time financial statement draw upwwwboehringeringelheimcom annualreportboehringeringelheimcomb e h r n g e r n g e l h e annual report value innovationf na n ci l h ig h li g h ts u mm ry r ep r amount million eur indicate change net sale region europe americas asia australia africa business prescription medicine consumer health care animal health biopharmaceutical industrial customer sale research development personnel cost average number employee operate income operating income net sale income taxis income taxis net sale shareholder equity return shareholder equity cash flow investment tangible asset depreciation tangible asset product product prescription medicine consumer health care net sales eur million change net sale eur million change spiriva dulcolax pradaxa buscopan micardis mucosolvan trajenta jentadueto pharmaton ove rv iew company shareholder perspective key aspect highlight medicine group management report consolidate financial statement product portfolio c n e n company product portfolio shareholder perspective brand prescription medicine key aspect respiratory disease corporate body cardiovascular disease highlight medicine metabolic disease oncology group disease central nervous system management report infectious disease information group company report economic position consumer health care report postbalance sheet date event cough cold risk report sore throat report expect development pain gastrointestinal disease consolidate vitamin supplement financial statement leg vein health urological disease overview major consolidated company consolidate balance sheet animal health consolidated profit loss statement food produce animal swine cash flow statement food produce animal poultry statement change group equity food produce animal cattle note consolidated companion animal horse financial tatement companion animal small animal auditor report u r c p n boehringer ingelheim group world lead pharmaceutical company headquarter ingelheim germany boehringer ingelheim operate globally affiliate total employee focus familyowned company found research develop manu facture marketing new medication high therapeutic value human veterinary medicine social responsibility important element corporate culture boehringer ingelheim include worldwide involvement social project initiative make health care employee respect equal opportunity reconciliation work family life form foundation mutual cooperation thing company focus environmental protection sustainability shareholder perspective boehringer ingelheim christian boehringer chairman shareholders committee h e h r e h l e r p e r p e c v e look year history boehringer ingelheim apparent change undergone transition small factory manufacturing tartaric acid niederingelheim germany start employee international researchdriven pharmaceutical company departure traditional business area bake powder recently generics business establish new segment biopharmaceutical shareholder perspective boehringer ingelheim production increase employee number globally today remain important innovation innovation make possible create add value difference new effective medicine human pharmaceutical animal health provide prescriptionfree medication good formulation shareholder family primary responsibility create envi ronment innovation possible know innovation industry happen overnight average take year develop new dicine initial research idea market market launch depend country year leave patent prescription medicine expire plan provide reliable financial framework long term today important give upheaval global pharmaceutical market increasingly age population finance social insurance contribution few young people lead change healthcare system change take place rapidly researchdriven pharmaceutical company need innovation level order actively shape upheaval necessary que tion traditional method find new solution researchdriven pharmaceutical industry contribution obvious regard increase life expectancy regard fact live long healthy year equally increase markedly found big strength familyowne company ability adapt maintain longterm independence year announce initiate conclude numerous change order maintain competitiveness future want concentrate busi ness lead position business certain critical mass case generic business usa context decide summer sell roxane business month later announce enter exclusive negotiation sanofi regard strategic swap overthecounter otc medicine business sanofis animal health business result exchange company lead competitor different discipline international pharmaceutical market shareholder perspective boehringer ingelheim longterm strategy shareholder family involve discuss agree change board manage director way con d er eat careful plannable dr andreas neumann fill standalone human resource position want emphasise significance f unction future requirement account longterm inter national staff development planning creation separate innovation depart ment dr michel pairet helm commitment research deve lopment important medicine add value succession procedure set mid regard chairman board manage director decision direct ensure contin uity futureoriente outlook hubertus von baumbach successor professor andreas barner prepared challenge face company knowledge company business area experience member board manage director colleague drive forward transformation boehringer ingelheim order strengthen paramount goal maintain independence company long term people boehringer ingelheim bring innovation new management position human resource take human factor account view adapt longterm international staff development planning orient future requirement involve increase focus corporate culture particularly impor tant times change culture boehringer ingelheim define openness mutual esteem empathy trust respect passion importance humaneness company emphasise ernst boehringer young son company founder human intellect priority intellect complement heart brain bring human closeness shareholder perspective boehringer ingelheim shareholder family want thank employee boehringer ingelheim work carry effort wealth idea courage face new challenge readiness strike new direction offer opportunity forward topic innovation boehringer ingelheim independent familyowne company want continue progress benefit patient sign christian boehringer chairman shareholders committee key aspect boehringer ingelheim andreas barner wolfgang baiker hubertus von baumbach joachim hasenmaier michel pairet allan hillgrove andreas neumann leave right board manage director k e p e c eventful year boehringer ingelheim medicalresearch business perspective look year company record submission approval product launch year history success reflect significant growth major strategic decision set course past year longterm growth key aspect boehringer ingelheim boehringer ingelheim wellbee patient animal central field human pharmaceutical animal health aim develop new effective medicine disease high unmet medical need new treatment option innovation prerequisite sustainable growth success past financial year speak regard market environment challenge entire pharmaceutical industry al global pharmaceutical market continue grow market access innovative medicine prove increasingly difficult time price pressure continue rise country key market usa japan europe feel impact predominantly prescription medicine important business despite succeed expect moderate singledigit growth local currency term achieve total net sale billion euro big sale contributor remain respiratory medicine spiriva anticoagulant pradaxa micardi treat high blood pressure achieve sale billion euro diabete medicine trajenta jardiance major growth driver ofev product patient idiopathic pulmonary fibrosis ipf innovative medicine human pharmaceutical animal health product determine growth company success future robust investment plan international research development major element consider investment billion euro international research development human pharmaceutical year right approach billion euro preclinical research billion euro collaboration external partner research team currently work total different project schwerpunkte boehringer ingelheim outstanding example success research clinical trial new diabetes medicine jardiance firstever diabete medicine able reduce number death cardiovascular disease specially design clinical trial milestone praxbind specific reversal agent oral anticoagulant pradaxa develop successful year respiratory medicine portfolio spiriva respimat receive approval food drug adminis tration fda indication asthma new chronic obstructive pulmo nary disease copd medicine spiolto approve use eu country usa start year european commis sion issue authorisation ofev treatment rare respiratory disease idiopathic pulmonary fibrosis pipeline continue promise phase ii trial new biological investigational active ingredient treatment skin condition psoriasis show improve condition skin quickly long current gold standard ustekinumab central nervous system therapy area delight excellent progress clinical testing substance treatment schizophrenia alzheimer disease example new medicine combat specific type lung cancer designate drug authority fda breakthrough therapy assume pharmaceutical market continue change rapidly make important retain scope growth innovation continue successful market future include focus core competency area business play lead role globally potential global leader schwerpunkte boehringer ingelheim able headway major strategic decision include sale roxane generics business end year announce ment enter exclusive negotiation sanofi exchange overthecounter otc medicine business sanofis animal health business mean boehringer ingelheim way traditional otc medicine business convince new strong animal health business exceptionally place growth lead global company step easy deci sion despite evident mark consolidation market segment certain otc boehringer ingelheim possible sanofi climb world number business important step future decision invest half billion euro expansion biopharmaceutical production facility pioneer field year experience company produce biopharmaceutical medicine worldwide establish new largescale biopharmaceutical production facility vienna austria future production active substance cell culture account future requirement production capacity contract manufacturing inhouse biopharmaceutical addition expand production pocketsize inhaler respimat respiratory medicine portfolio ingelheim dortmund facility germany research development pipeline wellstocke new research strategy implement ensure longterm innovation performance mediumterm current product launch expansion business activity emerge market strengthen growth business area key aspect boehringer ingelheim activity company build global workforce commit motivated employee know innovative strength success boehringer ingelheim fundamentally knowledge experience commitment expertise like thank employee outstanding performance exceptional team spirit signed sign andreas barner wolfgang baiker signed sign hubertus von baumbach joachim hasenmaier sign sign allan hillgrove andreas neumann sign michel pairet corporate body boehringer ingelheim co r p r e bo e shareholders committee board manage director christian boehringer prof dr dr andreas barner chairman shareholders committee chairman board corporate board division human christoph boehringer resources corporate board division research erich von baumbach jr development medicine isabel boehringer dr wolfgang baiker corporate board division biopharmaceutical dr mathias boehringer operation hubertus von baumbach corporate board division finance advisory board dr joachim hasenmaier egbert appel corporate board division animal health chairman advisory board consumer health care trustee martin hilti family trust president hilti foundation allan hillgrove corporate board division kurt beck pharma marketing sale ministerpresident dr andreas neumann dr andreas kreimeyer corporate board division human resource member board executive director research executive director basf se dr michel pairet corporate board division research jan rinnert nonclinical development chairman board management heraeus hold gmbh highlight medicine boehringer ingelheim progress patient medical milestone boehringer ingelheim continue long tradition commit kidney disease compare placebo reduce clinically te resource create value innovation relevant renal event datum advance public health significant progress measure extensively discuss regulatory authority diabete patient feel value advance specialist worldwide treatment innovation highlight value approval praxbind europe high innovation empareg outcome study light research development innovation approval praxbind important patient atrial fibrillation approval half people living type diabetes praxbind mean pradaxa blood thin agent eventually die cardiovascular complication indicate prevention stroke patient atrial patient significant reduction life fibrillation specific reversal agent praxbind pro expectancy year september vide physicians additional tool reversal main result large cardiovascular outcome trial anticoagulant effect pradaxa need rare empareg outcome publicly share major dia situation emergency surgeryurgent procedure life bete congress empagliflozin jardiance compound threaten uncontrolled bleed approval p raxbind treatment type diabete reduce risk die base datum healthy volunteer result cardiovascular cause interim analysis realworld reverse ad patient study clinical trial result empareg outcome reverse ad study datum simultaneously publish study subsequently present show new england journal medicine present major cardiovascular effect empagliflozin see high international congress june boehringer ingelheim risk patient suffer heart failure renal commit make praxbind available widely possi impairment beginning study additional datum ble worldwide continue obtain regulatory approval empareg outcome present late suggest country pradaxa license drug significantly slow progression diabetic highlight medicine boehringer ingelheim cardiovascular advance anticoagulation care regulatory authority europe commitment innovative care area acute stroke treatment approve praxbind idarucizumab patient risk devastate blood clot actilyse approve specific reversal agent boehringer ingelheim continue evolve treatment acute ischaemic stroke pradaxa dabigatran etexilate anticoagulant landscape boehringer ingelheim launch boehringer ingelheim begin research enrolment patient angel initiative initiative pro praxbind recircuit recover dvtpe vide doctor tool resource approval pradaxa stroke preven study late indication treat support require set stroke net tion atrial fibrillation occur ment prevention recurrence work improve treatment acute inhouse development deep vein thrombosis dvt pulmo ischaemic stroke advance pradaxa reversal agent p raxbind nary embolism pe pradaxa local stroke care globe boehringer ingelheim scientist approve country globally demonstrate company continue respiratory important year boehringer ingelheim proud safety nintedanib investi chance manage symptom well heritage respiratory disease gate phase iii trial patient early stage disease important year ofev nintedanib systemic sclerosis rare life allow patient remain active receive approval eu japan threaten disease long time treatment patient idiopathic chronic obstructive pulmonary year approval pulmonary fibrosis ipf ipf rare disease copd progressive lung dis europe spiriva respimat avail severely debilitate fatal lung disease ease copd predict able use asthma coun characterise lung tissue scar lead cause death globally try include extensive clini cause loss oxygen transfer spiolto respimat tiotropiumolo cal evidence reflect inclusion blood ofev slow disease progre daterol launch spiriva respimat late version sion significantly available treatment patient copd piolto global initiative asthma gina country recom build tiotropium active ingredi report mend update international ipf ent spiriva study demonstrate treatment guideline efficacy spiolto respimat offer patient highlight medicine boehringer ingelheim oncology huge unmet need lung cancer boehringer ingelheim continue effort comparator treatment giotrif vargatef improve cancer treatment particularly patient nintedanib lung cancer treatment patient suffer lung cancer headtohead trial adenocarcinoma lung provide foun compare afatinib giotrifgilotrif estab dation boehringer ingelheim lung cancer portfolio lishe agent strengthen profile compound advance approve treatment lung cancer squamous development lung cancer example global piv cell carcinoma lung afatinib show positive otal trial programme underway bi survival datum result regulatory submission treatment option patient fda european ema new lung cancer progress egfr tki treatment indication afatinib approve patient boehringer ingelheim aim achieve approval specific type egfr mutationpositive non compound lung cancer small cell lung cancer indication drug boehringer ingelheim strategy aim develop demonstrate delay tumour progression compare e innovative treatment option patient gefitinib egfr specific treatment lung haematological cancer develop innovative cancer trial afatinib tolerable immunooncology treatment metabolic disease grow portfolio diabetes stage addition result empareg outcome treatment need complex condition overall diabetes portfolio grow significantly underway empareg outcome alliance partner eli lilly com jardiance large cardiovascular outcome trial pany launch different diabetes carolina carmelina trajenta product major geography addition trajenta track complete time linagliptin jentadueto linagliptinmetformin treatment diabetes require holistic jardiance empagliflozin approach medication boehringer ingelheim launch combination drug glyxambi linagliptin conduct introdia world large empagliflozin synjardy empagliflozinmetformin survey well understand early conversation biosimilar insulin approve physician patient type diabe europe new insulin glargine product abasaglar tes patient datum survey pre launch european country sente late serve basis japan develop solution improve early conversation clinical trial regulatory submis type diabetes sion combination tablet meet individual highlight medicine boehringer ingelheim central nervous ystem cns mystery human brain boehringer ingelheim concentrate development pde solution illness like identify brain chemistry responsible inhibitor phase ii study alzheimer schizophrenia common debili boehringer ingelheim include addition pharmacological treatment tat symptom range brain research activity field psy support therapy sensible disease include schizophrenia chiatry include treatmentresistant necessary explain dr jrgen ree alzheimer disease treatmentresis depression compound investi therapeutic area head cns accord tant depression major symptom gation design increase brain ingly employ element like cog cognitive impairment mean reduce neuroplasticity allow nitive performance training context mental ability concentrate think learn form new connection nerve study investigate memorise lead signifi cell way hope cog positive effect individual not problem social life everyday nitive impairment normalise treatment element boost function therapeutic area cns boehringer ingelheim plan pre combination truly innovative wellstocked pipeline include ent phase ii result approach industry couple molecule early stage clinical recognise medication immunology success immunology research past year show innovation month nearly triple percentage bi investigate immunology boehringer ingelheim patient risankizumab compare disease immunology abbvie frontrunner biologic ilp ustekinumab long standing heritage immunol blocker anticipate substance light current high potential ogy partner abbvie good risankizumab demonstrate risankizumab second frontrun way ensure medicine reach phase ii trial month ner molecule boehringer ingelheim right people achieve potential cent patient moderateto immunology pipeline maximise boehringer ingelheim severe plaque psoriasis maintain number patient world involve research development clear clear skin pasi access promise immunology space year risankizumab high dose group potential treatment approve continue invest research compare cent patient critical public health perspective development early phase ustekinumab patient achieve boehringer ingelheim en compound immunology pipeline skin clearance significantly fast tere agreement form global proactively build pipeline month long collaboration abbvie bring capability important area ustekinumab completely clear skin ward advanced investiga pasi maintain tional compound risankizumab group management report boehringer ingelheim group management report g r u p n age e n r e p r information group company report economic position report postbalance sheet date event risk report report expect development konzernlagebericht grundlagen des konzerns group management report information group compani es boehringer ingelheim information group company group management report information group company group business model boehringer ingelheim promise product authorisation boehringer ingelheim familyowne company obtain ofev offer people establish base ingelheim rare fatal respiratory disease idiopathic pulmonary germany focus company research fibrosis ipf new treatment option praxbind development production sale innovative antidote anticoagulant pradaxa revoke pharmaceutical improve health quality effect minute intake life contribute great therapeutic b enefit human animal health affiliate business aim boehringer ingelheim drive company employee worldwide forward innovative development exist group achieve net sale eur billion product portfolio organic growth cooper make world pharmaceutical company boehringer ingelheim business activity cover prescription medicine consumer health care net sale business eur million animal health biopharmaceutical industrial cus tomer prescription medicine prescription medicine form core company activitie medicine boehringer ingelheim long standard treatment respiratory disorder consumer health care cardiovascular disease metabolic disease oncology disease central nervous system com pany big revenue contributor spiriva treat chronic obstructive pul animal health monary disease copd approve use asthma patient pradaxa prevent stroke patient atrial fibrillation prevention treatment thromboembolic biopharmaceutical disorder micardis estab lishe year treatment hypertension sig nificant contribution company success trajenta jardiance industrial customer sale impressive trajectory treat type diabete support positive growth group management report net sale region eur million australia africa aaa gain significance group make group total net sale big market usa japan germany account sale year research development rd line boehringer ingelheim mission statement europe primary goal research develop innovative medicine therapie treatment disease asia satisfactory treatment available australia africa aim time major contribution america aaa area need treatment high occupy lead position major indication area achieve aim addition research ation external partner boehringer development team boehringer ingelheim draw ingelheim operate global research network global network comprise academic group biotech company addition expand product consumer health care dulcolax buscopan portfolio partnership agreement systematic mucosolvan pharmaton com inlicense technology product year pany high selling medicine review example boehringer ingelheim con clude licensing agreement korean company animal health major pillar boehringer hanmi pharmaceutical development target ingelheim business pig vaccine ingelvac circoflex therapy lung cancer patient certain epidermal treat porcine circovirus type signifi growth factor receptor egfr mutation not product animal health term sale boost boehringer ingelheim competitiveness animal boehringer ingelheim research development health area long term company enter exclu activity basis company success sive negotiation french company sanofi sa generally innovative prowess december aim trading sanofis animal primary driver group positive growth health business boehringer ingelheim consumer recent year inhouse research development health care business party count continue priority future example transaction finalise end consistent implementation strategy research facility vienna austria inaugu biopharmaceutical business comprise manufacture rate november oncological research take place ownbrand marketable product development lab facility order open new therapy option biosimilar world lead company doctor help people tumour investment process development contract manufacturing facility amount eur million commercial production thirdparty customer financial year employ average boehringer ingelheim achieve majority people research development site sale americas europe total eur billion invest region revenue region asia research development new medicine group management report information group compani es boehringer ingelheim research development expenditure eur million net sale prescription medicine expenditure eur million prescription medicine net sale average number employee investment tangible asset investment infrastructure eur million corresponding group net sale spiolto respimat base tiotropium enhance forecast level previous year long act betaagonist olodaterol large tovito phase iii clinical trial programme investigat human pharmaceutical ing efficacy safety spiolto respimat boehringer ingelheim carry research develop include clinical trial patient ment prescription medicine consumer enrol total health care business facilities usa germany austria italy japan year aboveaverage number new datum subgroup analysis pivotal registration new product obtain sub phase iii tonado studies present ameri mitte key focus research work thoracic society congress at denver datum follow indication area show spiolto respimat provide lung function benefit patient copd right start respiratory disease maintenance therapy great benefit show cardiometabolic disease cardiovascular metabolic patient moderate copd gold sum disease mer publication phase iiib otemto oncology trial respiratory medicine provide new data disease central nervous system show spiolto respimat offer consistent clinically immunology meaningful improvement quality life versus placebo patient copd expenditure rd prescription medicine account net sale generate business landmark year boehringer ingelheim respiratory year company brand stiolto respimat canada inspiolto active field emerge leader lung dis respimat buhl r maltais f abrahams r et al tiotropium olodaterol fixeddose ease year therapeutic area ta respiratory combination versus monocomponent copd gold eur respir j bring new treatment advance patient apr buhl r abrahams r grnke l et al tiotropium plus olodaterol fixeddose combination therapy provide lung function benefit compare tiotropium irrespective prior treatment longacting broncho chronic obstructive pulmonary disease copd spiolto dilator post hoc analyse year study ats congress abstract respimat tiotropiumolodaterol receive approval singh ferguson gt bolitschek j et al tiotropiumolodaterol show clini cally meaningful improvement quality life re med doi http canada japan european country dxdoiorgjrme group management report energito study show lung function midyear ofev include update interna improvement spiolto respimat superior tional atsersjrsalat clinical practice guideline inhale corticosteroid therapy fluticasone propionate treatment idiopathic pulmonary fibrosis salmeterol fixeddose combination fdc patient mark important step forward patient care moderate severe copd committee note high value ofev patient important outcome disease progression meas spiriva respimat new class inhale asthma ured decline rate force vitality capacity fvc treatment approve decade year approval europe spiriva respimat boehringer ingelheim expand research available use asthma country include nintedanib progressive fibrotic lung disease usa september food drug devastating condition rare disease administration fda approve spiriva respimat systemic sclerosis commonly accompany pulmonary tiotropium bromide inhalation spray use treat manifestation december senscis safety ment asthma longterm oncedaily maintenance efficacy nintedanib systemic sclerosis phase iii treatment patient year age old study begin recruit patient study include patient systemic sclerosis associate interstitial spiriva softmist inhaler respimat include lung disease addon asthma therapy recent global initia tive asthma gina report global strategy focus boehringer ingelheim research activity asthma management prevention field cardiovascular disorder mark advancement anticoagulation care boehringer ingelheim begin boehringer ingelheim announce present result patient study investigat european commission ec approve ninte ing effect praxbind specific reversal agent danib treatment idiopathic pulmonary fibrosis anticoagulant pradaxa revoke effect ipf follow expedite review positive chmp minute intake realworld emergency setting committee medicinal product human use interim result ongoing phase iii reverse ad opinion november nintedanib market study present international society throm eu japan usa countries brand bosis haemostasis congress toronto canada june ofev ipf rare severely debilitate fatal simultaneously publish new england journal lung disease ofev boehringer ingelheim medicine praxbind support care p radaxa offer new treatment option patient treat patient emergency situation provide devastating disease physician additional tool reversal anti coagulant effect pradaxa need pivotal phase iii inpulsis trial phase ii tomorrow trial demonstrate ofev indication area metabolic disorder focus consistently slow disease progression patient research development drug treatment ipf reduce annual decline lung function diabetes result cardiovascular outcome trial empareg outcome demonstrate jardiance empagli flozin reduce death cause cardiovascular compli beeh km derom e echavesustaeta j et al energito efficacy safety oncedaily combine tiotropium olodaterol versus twicedaily combine cation overall cardiovascular effect jardiance fluticasone propionate salmeterol poster pa ers abstract number see high risk patient suffer group management report information group compani es boehringer ingelheim heart failure renal impairment study beginning incidence adverse event nintedanib boehringer additional data empareg outcome show ingelheim second approve lung cancer treatment jardiance significantly slow progression evaluate indication lung cancer diabetic kidney disease compare placebo see initiation registration trial investigate reduce clinically relevant renal event triple angiokinase inhibitor patient advance receive approval launch colorectal cancer patient malignant pleural combination drug glyxambi linagliptinempagliflozin mesothelioma synjardy empagliflozinmetformin clinical trial regulatory submission additional german institute quality efficiency health combination tablet meet individual treatment care iqwig step rating afatinib need complex condition underway stand therapeutic benefit base positive overall empareg outcome jardiance survival datum show comparison chemotherapy large cardio vascular outcome trial carolina independent trial patient frequent carmelina trajenta schedule complete egfr mutation del nintedanib receive positive time evaluation health technology assessment body uks national institute health care excel indication area oncology boehringer ingelheim lence nice iqwig successfully advanced research development pipeline compound market treatment approval giotrif vargatef lay aim provide new treatment option offer foundation boehringer ingelheim lung cancer port patient add therapeutic value contribute quality folio compound advance develop life improvement ment lung cancer example global pivotal eluxa trial programme underway bi boehringer ingelheim continue effort treatment option patient lung improve cancer treatment particularly patient cancer progress egfr tki treatment com suffering lung cancer head head trial com pound grant breakthrough therapy designa pare afatinib giotrifgilotrif establish tion fda boehringer ingelheim aim agent strengthen profile approve approval compound treatment lung cancer squamous cell carcinoma lung afatinib show positive survival datum lung cancer boehringer ingelheim strategy result regulatory submission fda aim develop innovative treatment option ema new indication afatinib patient hematological cancer broaden approve indication egfr mutationpositive nonsmall presence field immunooncology cell lung cancer drug delay tumour progression comparison gefitinib trial afatinib research team central nervous system cns dis tolerable comparator treatment similar ease boehringer ingelheim focus identify inzucchi et al empagliflozin cardiovascular outcome patient advance squamous cell carcinoma lung luxlung openlabel type diabete mellitus high cardiovascular risk scientific randomise control phase trial lancet oncology zinman b et al empagliflozin cardiovascular outcome mortality dois type diabete n engl j med park k et al afatinib versus gefitinib firstline treatment patient wanner c et al oral presentation empagliflozin cardiovascular advanced nonsmall cell lung cancer harboring activate egfr mutation come patient type diabete chronic kidney disease asn result global randomize openlabel phase iib trial luxlung kidney week abstract sapo j soc neph b lba oral presentation esmo asia congress singapore soria et al afatinib versus erlotinib secondline treatment patient december group management report brain malfunction responsible launch otc ibuprofen therapy japan uniquely important symptom share different brain disease position pain relief woman schizophrenia alzheimer disease animal health major symptom find disease research development work field animal cognitive impairment wellstocke cns pipeline health boehringer ingelheim focus innovative molecule advanced stage develop vaccines protection livestock pet ment include pdeinhibitor pharmaceutical product facilities usa phase ii clinical development germany china mexico japan netherlands focus research new drug development cns team confident advance future therapeutic solution vaccine clinical program year boehringer base local pathogen pathogen variant ingelheim get close new treatment option imperative present key market region patient disease local research development production facility immunology major important result achieve phase ii psoriasis trial boehringer ingelheim past year eur million invest biologic risankizumab risankizumab ilp expansion exist facility con blocker clear skin well fast long struction centre clinical research china current gold standard ustekinumab investment demonstrate company commitment intention sustainably strengthen position month patient moderate animal health severe plaque psoriasis maintain clear clear skin pasi risankizumab high dose group half year eu country grant compare patient ustekinumab patient authorisation improve vaccine achieve skin clearance significantly fast porcine respiratory reproductive syndrome prr month long usteki ingelvac prrsflex eu piglets reprocyc prrs eu numab completely clear skin pasi maintain sow decentralise process specially devel month nearly triple percentage ope vaccine account different immune patient risankizumab compare ustekinumab reaction adult pig versus piglet product ingelvac prrsflex eu boehringer ingelheim able boehringer ingelheim invest research offer prrs vaccine european market development range early phase compound specially design use piglet minimise immunology pipeline indication crohns symptom respiratory disorder reduce trans disease ulcerative colitis lupus nephritis mission virus active immu nisation healthy swine age day consumer health care business boehringer ingelheim contrast reprocyc prrs eu vaccinate successfully launch product mucoangin sore young sow breed sow affect prrs throat spray dulcosoft europe mucoangin sore phase production regardless throat spray contain ambroxol indicate pregnant pain relief acute sore throat dulcosoft gentle laxative japan eve ex successfully globally boehringer ingelheim animal health business launch year eve product range receive product authorisation group management report information group compani es boehringer ingelheim biopharmaceutical boehringer ingel heim invest production capacity boehringer ingelheim commit strategic decision respiratory disease product spiriva handihaler actively enter biosimilar business respimat platform meet demand increase access highquality biologic market patient world company focus drive wave biosimilar compound immu cover increase demand antidiabetic nology oncology work molecule portfolio boehringer ingelheim invest preclinical development pivotal phase iii eur million production facility mexico city trial bi biosimilar candidate humira koropi greece bi biosimilar candidate avastin initiate programme track animal health field animal health boehringer ingelheim production primarily active north central america human pharmaceutical production network comprise facility manu overarch aim production human pharma facture vaccine facility nutraceutical ceutical reliable market launch product network contract manufacturer pharmaceutical routine care patient highquality product construction new chinese facility pharmaceutical taizhou continue apace asian location soon join production network major end boehringer ingelheim revise supply component animal health growth strategy strategy motto volume value facility focus manufacture vaccine supply network set reorganise porcine avian disease chinese market year reflect requirement business biopharmaceutical production facility focus manufacture biopharmaceutical activity boehringer ingelheim product high relevance group germany biberach austria vienna usa manufacturing technology require specific degree fremont china shanghai comprise manufacture expertise operate production facility ownbrand marketable product actilyse country year review metalyse praxbind process development divide pharmaceutical chemical nbe biosimilar world biopharmaceutical facility pro lead company process development contract duction facility medical product manufacture commercial production thirdparty customer boehringer ingelheim cover production facility supplement entire bio pharmaceutical value chain genetic external contract manufacturer primarily focus development cell follow manufacture manufacture product advance fill finish pharmaceutical product stage life cycle ensure reliable competitive product launch global market supply compari supply prescription medicine consumer health son previous year see overall increase care product close cooperation external partner use capacity production facility active secure boehringer ingelheim access technology substance praxbind successfully produce currently available internal production boehringer ingelheim launch american portfolio european markets group management report company promise biopharmaceutical develop employee protection examine regular audits ment project strong demand market order continuously identify potential area contract manufacturing basis decision improvement significant investment expand bio pharmaceutical production capacity boehringer ingel extensive work analyse decontaminate soil heim set new industrialscale biopharma ingelheim facility germany contin ceutical production facility vienna active sub ued order ensure appropriate protection stance cell culture new environment necessary result techni production facility operation cal progress issue analyse push ahead establish new precisely today expert field geochemistry facility shanghai biopharmaceutical develop environmental toxicology engineering consult ment service chinese international customer advice implement measure pilot facility manufacture biopharmaceutical public date progress clinical trial supply successfully go production delivery gmp standard clinical trial order contribution reduce global sample customer build co emission set ambitious house commercial facility complete goal reduce co emission term sale expect operation plan compare value aim put focus potential energy saving occupational safety environmental reduction emission promote exchange protection expertise company facility coordi protection employee facility nating project international level environment sustainable use natural resource promotion environmental awareness health safety employee high priority major component company mission state boehringer ingelheim reflect high ment prime importance boehringer ingelheim global safety standard guideline past year boehringer ingelheim implementation safety culture groupwide environment award german federal state safe initiative launch aim fur rhineland palatinate outstanding effort pro ther reduce number workplace accident tect environment nature natural resource roll international facility compliance social environmental aspect focus global measure human behaviour anchor corporate philosophy year order achieve ambitious target accident company strive maintain natural resource frequency rate afr accident million advocate environmental awareness hour work afr stay outside company observe social ecological slightly level prior year concern way ensure enjoy sustainable financial success groupwide company develop bind stand ards term environmental protection health safety work internal guideline reflect respec tive countryspecific legal requirement compliance standard status environmental group management report information group company boehringer ingelheim report economic position employee report company aim strengthen appeal boehringer ingelheim employ boehringer ingelheim employer current people worldwide regional perspective future employee boehringer ingelheim number staff america reduce recipient award effort area number employee europe aaa include name innovative region increase company world news agency thomson reu ters award proof pioneer approach average number employee region longterm strategy boehringer ingelheim hr work america addition company receive rating europe student survey conduct asiaaustraliaafrica aaa international research consulting firm universum aim identify popular german employer year boehringer ingelheim enable major success factor positive growth trainee obtain practical work experience group innovative dedicate reliable staff variety area company past accordingly commit actively devel oping year company receive high rating employer support employee order good pre quality pharmaceutical industry prakti pare challenge ahead comprehensive kantenspiegel trainee satisfaction survey training system set great store big employer brand study germany acquisition technical expertise promote social skill boehringer ingelheim name employer year germany austria china addition competitive salary boehringer ingelheim receive mark auditor international offer benefit employee benefit independent employer institute major hr include company pension plan flexible homebase category talent strategy staff plan work option countless healthrelate benefit performance management onboarde significant segment corporate strategy evidence high appeal development talent management department remit ensure opportunity company employee employability staff promote wide range potential recruit opportunitie innovation work motivate employee nurture talent develop social responsibility individual take social responsibility important aspect corporate culture commitment wellbee vocational training major importance patient employee family focus boehringer ingelheim understand range project addition support people social responsibility company offer career oppor need initiative particularly country tunitie great number young people region active company time tie talented wellqualifie workforce company activity focus protect main young professional company taine environment drop demographic change young profes sional start career boehringer ingelheim addition longterm initiative boehringer ingel germany different scientific technical heim provide help urgently need commercial field example boehringer ingelheim help asylum group management report seeker germany gift donation area diversity market reflect work accomodation facility refugee reception center force create work environment embrace provide food supply boehringer ingelheim diversity difference pillar involve integration refugee interested corporate culture boehringer ingelheim con party invite tour facility tribute factor company success introduce business give presentation german apprenticeship sys boehringer ingelheim involve tem furthermore refugee integrate herzenssache schlaganfall take stroke heart apprenticeship form oneyear awarenessraising initiative year campaign introductory training programme name good national patient information campaign receive health medium award initia major pillar social commitment make tive launch boehringer ingelheim health mmh initiative year boehringer promote project raise awareness atrial ingelheim partnership ashoka global fibrillation associate risk stroke nonprofit organisation aim partnership improve public perception independent organi integrate health major factor people live sation world involve world include family social envi initiative awarenessraise event carry ronment aim identify support promise city initiative idea improve health order achieve support deutsche gesellschaft fr kardiologie make health currently promote german cardiac society dgk select social entrepreneur world attempt come effective solution boehringer ingelheim continues actively support healthcare sector research science culture longterm partnership academic institution serve underline company social commitment company encour systematic focus research development aged boehringer ingelheim employee example boehringer ingelheim invest country work mmh initiative research project investigate infection porcine mmh youth venture project entrepreneurial skill circovirus type pcv associate disease develop work design social pro addition support sponsor scientific activity ject actively support mentor workforce scientist award annual boehringer initiative support executive residence ingelheim fen research award neuroscience eir mmh insight india staff development pro heinrich wieland prize research biologically gramme programme give young manager active substance system opportunity support social entrepreneur health care sector project facility specific period time develop promote socially aware report economic approach business position integration experience cultural background personality boehringer ingelheim macroeconomic environment create openness different approach opinion global economy expand rate living motto value innovation moderate growth primarily weak devel global company important boehringer ingelheim opment emerge economy slowdown group management report report economic position boehringer ingelheim chinese economy decrease global demand measure consumer price index commodity detrimental impact main reason decrease oil price growth emerge economy compare previous year contrast cost service food rent increase rate inflation major industrialise country economic situa eurozone low tion show clear upturn course previous year support particular continued positive growth usa uk economic situation addition euro major currency eurozone show improvement stimulate boehringer ingelheim group dollar usd expansive monetary policy european central japanese yen jpy euro continue gener bank increase purchasing power private house ally weak course follow year hold contrast economic growth japan moder phase sharp devaluation quarter eat impetus monetary fiscal euro fluctuate relatively narrow range policy decision previous year lose effect compare currency relation dollar rate varied usd eur growth forecast global economy april usd eur january compare expect continue stable development japanese yen euro varied jpy eur usa uk furthermore economic april jpy eur january growth eurozone look set continue gradual slowdown china likely relate close economic global pharmaceutical market register growth tie emerge economy dampen financial year growth effect accord expert lead driven increase demand innovative medi slow growth country cine increase access medicine patient emerge economy particularly positive economic development continue noticeable rise demand generic otc medi germany economic output upturn cine industrialise country market support primarily positive development depressed health policy measure price regulation labour market increase purchasing power private increase cost pressure health care sys household rise private consumption addi tem patent pharmaceutical particular experienced tion regressive interest rate improve condition radical change market environment investment despite restrain growth world trade export grew support course business continually weak euro secure boehringer ingelheim independence long term strategic focus sustainable long view assume positive eco term competitive development company nomic growth germany continue forecast stable earning sound finance previous year growth strong expansion ger base approach principle year man economy hinder predict shrinkage review emerge economy associate low demand german capital good challenging year boehringer ingelheim exceptionally eventful year company average rate inflation price able record submission approval prod germany decrease compare previous year uct launch year history group management report outstanding example success research america region achieve sale growth development new diabetes medicine jardiance compare previous year sale active substance regulate blood sugar eur million total sale level firstever diabete medicine able america region remain big sale market reduce number death cardiovascular dis boehringer ingelheim eurodollar exchange rate ease people type diabete specially design positive impact revenue situation year trial approval praxbind antidote review adjust currency effect increase sale anticoagulant pradaxa revoke effect amount strong growth record minutes intake europe usa asiaaustraliaafrica aaa region major milestone boehringer ingelheim addition adjust currency effect boehringer ingel product ofev offer people rare fatal heim achieve revenues eur million respiratory disease ipf new treatment option region correspond stable share improve life expectancy receive market approval group total revenues europe region show spiolto improve posi low sale growth eur million tive therapy result spiriva treatment mean group sale copd product spiriva respimat receive addi region tional authorisation food drug admini net sale region currency tration fda use patient asthma eur million change adjust year herald implementation major america strategic decision aim help remain successful europe market future focus area busi asiaaustraliaafrica ness play lead role globally aaa global leader business gener ics sell company hikma pharmaceutical general sale growth conform expectation plc follow signing agreement com support good result clinical trial pany effect july assume transfer able launch promise new product success ownership ahead quarter fully push ahead wellestablishe product addition enter exclusive negotiation hand experience increasingly difficult french company sanofi sa december market situation constantly challenge market access aim trading sanofis animal health business grow price pressure key market usa boehringer ingelheim consumer health care business japan europe overall company assert party count transaction final despite difficult condition lay foun ise end dation growth boehringer ingelheim record sale eur mil boehringer ingelheim record operating result lion financial year correspond eur million corresponding return sale increase compare previous year percentage point previous value eur million exchange rate develop year return sale hand operating ment foreign exchange market associate result increase absolute term eur million exchange rate effect positive impact currency ad confirm expectation increase juste boehringer ingelheim growth rate stand sale costefficiency measure introduce positive effect group management report report economic position boehringer ingelheim eur million correspond key figure eur million change increase level net sale operating income micardi medicine treat high blood pre return net sale sure achieve sale eur million result operation year expect decline result boehringer ingelheim business activity divide loss exclusivity additional market prescription medicine consumer health care animal net sale eur million change health biopharmaceutical industrial customer spiriva net sale business currency pradaxa eur million change adjust micardis prescription medicine trajenta jentadueto consumer health care animal health regard regional distribution sale biopharmaceutical america share far industrial customer sale large market region boehringer ingelheim generate net sale eur million corre prescription medicine spond change compare previ total revenue prescription medicine ous year currency adjust sale perfor main pillar boehringer ingelheim business mance important market america activity revenue prescription medicine usa greatest impact development amount eur million include previous sale eur million addition positive year sale generics usa equivalent growth favourable exchange rate development major change currency adjust contributor increase revenue come compare previous year positive sale growth currency adjust successful launch numerous new product good result clinical trial experience secondbigg market europe account increase price pressure particularly estab revenue eur million sale remain lishe medicine number major market overall steady compare eur million boehringer ingelheim able assert subject significant exchange rate effect reve difficult environment lay foundation nue germany france particular low growth previous year net sale region previous year spiriva treat eur million change chronic obstructive pulmonary disease copd america big contributor sale europe achieve revenues eur million asiaaustraliaafrica aaa reporting period level previous year eur million aaa region achieve sale eur million second big sale contributor boehringer equivalent total sale prescription ingelheim anticoagulant pradaxa record sale medicine region show increase group management report compare year currency adjust sale america region large sale market eur million record japan big consumer health care business end financial year sale market boehringer ingelheim region cor slight decline revenue currency respond change compare pre adjust compare previous year achieve total vious year sale eur million consumer health care animal health consumer health care sale increase com revenue product animal health business pare previous year currencyadjuste increase eur million corresponding business boehringer ingelheim generate revenue increase previous year currency amount eur million adjust sale product livestock account large share eur million correspond big sale contributor consumer entire animal health segment health care segment dulcolax buscopan previous year big sale contributor mucosolvan pharmaton zantac products swine vaccine ingelvac circoflex accounting generate revenue significantly eur mil eur million pet segment revenue amount lion result positive growth ulcolax eur million big seller sale eur million net sale eur million change buscopan show slight increase ingelvac circoflex generate sale eur million positive result metacam achieve mucosolvan sale increase ingelvac prrs eur million duramune net sale eur million change dulcolax growth animal health segment sig buscopan nificant americas region accounting mucosolvan total sale big sale market boehringer pharmaton ingelheim business grow currency adjust eur million market par region europe generate high sale ticular sale increase eur million eur million correspond share global sale consumer health care business boehringer ingelheim see revenue grow europe sale year boehringer increase eur million rise ingelheim key european market germany revenues currency adjust accounting increase total revenue animal health business sale germany slightly previous year level aaa region end financial year sale sale uk experience particularly positive growth amount eur million increase compare previous year currency adjust region account increase currency adjust boehringer ingelheim consumer health care business aaa region record positive growth compare previous year recording sale eur mil lion china particular able achieve impressive group management report report economic position boehringer ingelheim growth net sale amount hold income increase eur million eur eur million million und contain income dismissal relate company biopharmaceutical sale biopharmaceutical contract manufac income taxis develop line result ture amount eur million represent operating activity increase eur mil growth compare previous year lion tax expense amount eur million note regard provision industrial customer sale german commercial law shareholder personal taxis industrial customer business consist arise group business activity recog party business field pharmaceutical chemi nise tax expense instead taxis present cal production contract manufacturing business withdrawal group equity taking pharma chemical sale eur million extraordinary effect account actual tax ratio achieve corresponding decrease revenue markedly high figure show profit currency adjust compare loss statement previous year financial year net income presentation expenditure income boehringer ingelheim group total eur mil operating expense boehringer ingelheim increase lion correspond increase eur million eur million financial year represent previous year level eur million ing rise compare previous year mate rial cost higher previous year com financial position e eur million make boehringer ingelheim financial management instru total sale personnel cost amount ment method aim secure liquidity mini eur million corresponding personnel mise financial economic risk optimise cost ratio slightly low cost capital appropriate capital structure previous year financial activity gear support e business strategy depreciation record increase eur million eur million operating expense global company exchange rate volatility significant rise compare previous year come impact boehringer ingelheim financial performance eur million item cost importance business associate block include commission licence payment supply relationships mean exchange rate develop dependent sale ment dollar constitute great individual risk framework groupwide financial operating result slightly high predict report foreign exchange risk calculate hedge eur million previous derivative financial instrument nature year eur million scope measure set group guideline regularly discuss approve relevant reporting period financial result amount committee standardise process eur million eur million compare previous year largely increase investment great importance boehringer ingel interest expense pension similar obligation heim strategic point view continuous investment group management report requirement longterm success develop cash flow lead increase liquidity eur ment company form basis profita million ble growth business division net asset total eur million invest tangible financial year boehringer ingelheim total intangible asset year review asset amount eur million increase eur million compare year boehringer ingelheim previous year tangible intangible asset total invest eur million expansion eur million fully cover consoli production capacity respimat inhaler date equity dortmund ingelheim facilities germany boehringer ingelheim microparts gmbh dortmund manufacture end year financial investment amount respimat inhalation system fill eur million correspond increase relevant active substance pharma ceutical eur million previous year value inventory production facility ingelheim ready global sale show growth eur million trade receivables rise eur million eur million addition new bi administrative office liquid fund include security current augurate ingelheim facility november asset stand eur million eur million represent investment eur million alltogether underline strategic role signi aforementioned change cash cash ficance location group equivalent group equity amount eur mil lion addition equity pension provision boehringer ingelheim invest longterm liability available group significant growth market china group plan long term total item amount invest eur million expansion eur million represent share manufacture facility chemical research total asset consequently longterm disposable development laboratory shanghai capital cover intangible tangible asset invento year research development field human rie trade receivable animal medicine remain priority boehringer ingelheim reflect investment provision high research facility germany austria year eur million liability increase margin usa ally eur million previous year cash flow amount eur million cash status show financial position flow operating activity increase eur mil remain resoundingly positive balance sheet lion previous year mean investment respective balance sheet ratio sum finance entirely fund generate boehringer ingelheim net asset financial earning company total eur million invest position confirm credential soundly finance tangible asset consideration subsidy profitable company eur million intangible asset term cash flow financing activity record outflow fund amount eur million overall change group management report report postbalance sheet date event boehringer ingelheim risk report report postbalance person responsible key business sheet date event function include process calculate assess risk groupwide risk information system ensure identify risk analyse boehringer ingelheim sign assess carefully follow appropriate classifi agreement development commercialisation cation category adequate countermeasure product belong therapeutic area immunology initiate implementation consistently significant income relate transaction monitor impact financial year closing transaction subject condition define year review internal auditing perform agreement target routine audit extraordinary audits world addition adherence legal end financial year requirement internal group guideline main aware event material focal point functionality system significance group company lead effectiveness internal control prevention reappraisal net asset financial position loss asset efficiency structure result operation process correspond adjustment optimisation initiate necessary risk report individual risk important risk boehringer ingel risk opportunity management heim expose broken follow aim risk management system implement specific category financial risk legal risk production boehringer ingelheim identify businessspecific risk environmental risk personnel risk sector particular risk jeopardise continue specific risk existence company early possible assess reduce reasonable level mean risk identify concrete suitable measure appear controllable mean specific manage ment procedure term abstract case assess risk context holistic risk risk completely control management endeavour account mean target management procedure regardless result opportunity opportunity management base probability occurrence strategy objective company individual business operate business unit integral financial risk groupwide planning management system relevant financial risk break responsible business function bear follow currency risk credit countryspecific risk direct responsibility early systematic identifica management financial investment risk tion analysis use opportunity boehringer ingelheim researchdriven innovative pharma currency risks ceutical company c urrent research development global orientation business activity result activity naturally consider relevant opportunity currency risk exchange rate volatility particularly detailed description project illustrate regard dollar japanese yen group research development chapter monitor quantifie risk regular interval group management report make predictable future business mean currently product liability insurance company relevant hedging strategy appropriate financial risk profile absolutely guarantee instrument forward exchange contract insurance coverage maintain reasonable resultant risk subsequently designate cost acceptable condition sufficient concrete controllable protect boehringer ingelheim claim loss potential claim loss credit countryspecific risk boehringer ingelheim expose credit furthermore product liability claim tie sub countryspecific risk result international business stantial financial resource management capacity activity portfolio trade account receivable detrimental company image event trade account payable identify market consider product unsafe ineffective extraordinary risk group usual level result unexpected effect boehringer ingel sector apply possible default risk heim closely monitor product development receivables largely hedge economic market attribute particular impor political risk continue carefully track tance benefitrisk ratio regular assessment credit countryspecific risk position regard risk abstract respond negative change timely manner risk regard concrete patent protection risk protection innovation trademark brand management financial investment risk patent right particular importance boehringer group pursue defensive investment strategy ingelheim research company commercial pro management financial asset reflect tective right increasingly target attack orientation portfolio focus european breach take necessary precaution economic monetary union emu government bond allow detect threat early stage com credit rating shortterm investment mence appropriate countermeasure defend legal bank result concrete position legal mean available controllable risk risk regard concrete legal risk production environmental risk business activity group expose legal quality management system compliance pro risk distinction regulatory liability cesse optimise close cooperation patent protection risk relevant authority order ensure compliance cgmp standard current good manufacturing practice regulatory risk future risk area continue high signifi boehringer ingelheim expose risk arise legal cance group classify abstract dispute proceeding official investigation legal administrative decision ongoing future order guarantee supply product proceeding predict regard resultant market implement measure guarantee risk abstract reliable highquality supply internal external customer addition supplier management liability risk procurement involve build internal marketing sale pharmaceutical expose standby capacity result risk concrete potential product liability risk boehringer ingelheim group management report risk report boehringer ingelheim report expect development risk area environment health safety keep close eye change sustainability ehss preemptively minimise sale market start respond ensure global adherence high safety standard current development costsave efficiency appropriate emergency plan draw improve measure initiate possible incident kind practise subject comprehensive quality testing regular overall statement risk situation interval result measure risk current perspective aware risk class concrete conjunction risk lead impairment company asset financial position personnel risk earning jeopardise continued existence boehringer ingelheim company expose boehringer ingelheim demographic change resultant risk affect lack appropriately qualified personnel report expect risk substantial impact company business activity potential risk development include longterm planning process year acquire strategic significance result boehringer ingelheim counter risk mean year review intense challenge comprehensive personnel concept regardless time boehringer ingelheim lay ethnic background gender religion offer foundation sustainable development long company employee development opportunity base term growth company major strategic vocational skill social expertise personal aptitude decision increasingly difficult market environment willingness responsibility accordance increase unpredictability business pose need company view counter major challenge entire pharmaceutical industry measure describe risk regard concrete continue require significant attention boehringer ingelheim regard competi sectorspecific risk tiveness important boehringer ingelheim expose business risk specific retain scope growth innovation pharmaceutical industry risk continue successful market future materialise past financial year change healthcare system usa increase continue renew product portfolio significance result impact boehringer financial year product launch form ingelheim continue class abstract basis future economic success clinical trial show new medicine offer addition loss exclusivity product establish patient significant therapeutic benefit example market risk associate development new diabetes medicine jardiance kind registration new product risk increasingly active substance regulate blood sugar include change restrictive requirement relate level reduce number death cardio pricing reimbursement sale market fre vascular incident patient type diabete quently price pharmaceutical product subject increase risk cardiovascular disease jardiance state monitoring regulation sell strategic alliance boehringer price pressure cheap generic drug cause ingelheim eli lilly longterm collaboration state reimbursement system boehringer ingelheim joint development marketing diabete active group management report ingredient continue comprise increase cost pressure healthcare system active ingredient ready market single particular reason few year approval praxbind few company prepare invest large amount specific reversal agent anticoagulant pradaxa proper development new medicine result europe usa ofev offer people significant price pressure major market rare fatal respiratory disease ipf new treatment option prescription medicine conjunction long improve life expectancy spiolto planning development cycle new product improve positive therapy result make business predictable require recog spiriva treatment copd lay foundations nise seize opportunity quickly hand offset expect decrease sale result subject cost strategy continual moni loss exclusivity right medicine tore adjustment end instigate initiative past year accelerate regard change healthcare system reaction change reduce organisational com increase price pressure particularly plexitie low cost base order create establish medicine major market potential investment secure regard increase challenge market access company longterm success difficult market new product expect low growth impetus environment hand potential result pharmaceutical industry come year measure introduce boehringer ingelheim assert difficult promising new product launch expect environment create basis growth operating result special effect expect minor increase reve company transaction slightly year level nue compare previous year adjust currency effect familyrun company long history strong tradition boehringer ingelheim primary aim main research development cost remain high tain firm independence competitiveness keep strategy drive growth promote longterm sustainable organic growth take new product future primarily product precedence shortterm profit target confi research development facility invest dent achieve ambitious target thank area care close investigation thera great innovative strength base comprehensive peutic benefit associate prospect success portfolio prospective product global presence comprehensive portfolio prospective product support highly qualified motivated promising study outcome newly approve employee current product launch expansion product significant sale potential justifie high emerge market boost growth area level investment research development business continue stand vision value plan invest research development innovation research develop innovative new pharmaceutical product similar level year product offer high medical benefit bring review market aim endeavour new medicine available enable doctor treat patient addition patent expiry attack patent effectively currently possible major challenge face researchdriven pharmaceuti cal industry increase investment rd big hurdle increase cost associ ate product approval context consolidated financial statement boehringer ingelheim consolidate financial statement c n l e f n n c l e e n overview major consolidated company consolidate balance sheet consolidated profit loss statement cash flow statement statement change group equity note consolidated financial statement auditor report overview major consolidated company boehringer ingelheim overview major consolidated company c h boehringer sohn ag co kg boehringer ingelheim boehringer ingelheim boehringer ingelheim gmbh europe gmbh international gmbh germany p r austria p r austria r boehringer ingelheim boehringer ingelheim rcv forschungsinstitut fr molekulare pharma gmbh co kg gmbh co kg vienna pathologie gesellschaft mbh ingelheim vienna boehringer ingelheim boehringer ingelheim pharma gesmbh vienna vetmedica gmbh ingelheim belgium boehringer ingelheim micropart gmbh dortmund czech republic scs boehringer ingelheim comm v brussels boehringer ingelheim boehringer ingelheim sro biopharmaceutical gmbh prague ingelheim china p boehringer ingelheim veterinary finland boehringer ingelheim research center gmbh co kg international trading shanghai hannover boehringer ingelheim co ltd shanghai finland ky espoo philippines norway boehringer ingelheim boehringer ingelheim phil inc manila norway ks asker poland boehringer ingelheim spzoo warsaw distribution p production r research development sole personally liable managing shareholder boehringer ag consolidated financial statement c h boehringer sohn grundstcksverwaltung gmbh co kg boehringer ingelheim auslandsbeteiligungs gmbh argentina r france p netherlands p taiwan boehringer ingelheim sa boehringer ingelheim boehringer ingelheim bv alkmaar boehringer ingelheim buenos air france sas paris taiwan ltd taipeh boehringer ingelheim animal health operation bv alkmaar australia greece p thailand boehringer ingelheim pty ltd boehringer ingelheim ellas ae new zealand boehringer ingelheim north ryde athens thai ltd bangkok boehringer ingelheim nz ltd auckland brazil p india turkey boehringer ingelheim brasil boehringer ingelheim portugal boehringer ingelheim ilac quimica e farmaceutica ltda india private ltd mumbai ticaret istanbul paulo boehringer ingelheim lda lisbon solana agro pecuaria ltda unilfarma lda lisbon indonesia p united kingdom arapongas pt boehringer ingelheim boehringer ingelheim ltd singapore indonesia jakarta bracknell canada boehringer ingelheim boehringer ingelheim singapore pte ltd singapore ireland usa p r canada ltd burlington boehringer ingelheim boehringer ingelheim corp south africa ireland limited dublin ridgefield connecticut chile boehringer ingelheim pty ltd boehringer ingelheim boehringer ingelheim ltda randburg pharmaceuticals inc italy p r santiago de chile ingelheim pharmaceutical pty ridgefield connecticut boehringer ingelheim ltd randburg boehringer ingelheim italia spa reggello usa corporation china p bidachem spa ridgefield connecticut south korea boehringer ingelheim shanghai fornovo giovanni roxane laboratories inc pharmaceuticals co ltd shanghai boehringer ingelheim korea ltd columbus ohio boehringer ingelheim china japan p r seoul boehringer ingelheim investment co ltd shanghai vetmedica inc boehringer ingelheim vetmedica nippon boehringer ingelheim spain p st joseph missouri china investment co ltd shanghai co ltd tokyo boehringer ingelheim boehringer ingelheim animal health ssp co ltd tokyo boehringer ingelheim roxane inc columbus ohio espaa sa barcelona operations china co ltd taizhou boehringer ingelheim boehringer ingelheim vetmedica japan co ltd boehringer ingelheim sa barcelona fremont inc columbia p tokyo europharma sa barcelona fremont california boehringer ingelheim boehringer ingelheim sa seiyaku co ltd yamagata laboratorios fher sa barcelona bogot venezuela boehringer ingelheim japan inc tokyo sweden boehringer ingelheim caraca denmark p boehringer ingelheim ab stockholm boehringer ingelheim mexico p r danmark copenhagen boehringer ingelheim switzerland promeco sa de cv boehringer ingelheim ecuador mexico city schweiz gmbh basel boehringer ingelheim vetmedica boehringer ingelheim del ecuador pharmaton sa lugano sa de cv guadalajara cia ltda quito consolidate financial statement consolidate balance sheet boehringer ingelheim consolidate profit loss statement c h boehringer sohn ag co kg ingelheim consolidate balance sheet asset millions eur note intangible asset tangible asset financial asset fix asset inventory account receivable asset security cash cash equivalent current asset defer charge prepaid expense defer taxis total asset liability equity millions eur note shareholder capital group reserve balance sheet currency conversion difference net income equity minority interest group equity negative difference acquisition company provision account payable liability defer charge defer taxis total liability equity explanation relevant section note consolidated financial statement consolidate financial statement c h boehringer sohn ag co kg ingelheim consolidated profit loss statement million eur note net sale change inventory internal work perform capitalise operating income total revenue material cost personnel cost amortisation intangible depreciation tangible asset operating expense operate income financial income hold income income taxis tax income taxis thirdparty share net income explanation relevant section note consolidated financial statement legal requirement disclosure shareholder personal taxis arise consolidated business activity tax expense allow taxis show withdrawal accrue group capital item consolidated profit loss statement value round millions eur disclose consolidated financial statement cash flow statement boehringer ingelheim statement change group equity c h boehringer sohn ag co kg ingelheim cash flow statement million eur income taxis include thirdparty share writedown writeup fix asset change provision pension cash flow change provision noncash income expense gain loss disposal fix asset change inventory change account receivable asset relate investing financing activity change trade account payable liability relate investing financing activity interest income interest expense income tax expense income income taxis pay cash flow operating activity investment intangible asset investment property plant equipment investment noncurrent financial asset proceed disposal intangible asset proceed disposal tangible asset proceed disposal noncurrent financial asset interest receive cash flow investing activity cash receipt grant interest pay cash payment owner cash receipt minority shareholder cash proceed borrowing loan cash flow financing activity change liquid fund cash relevant transaction change liquid fund exchange rate movement remeasurement financial fund financial fund change liquid fund drs financial fund change drs excl fixedasset security liquid fund security fix current asset source fund use fund consolidated financial statement c h boehringer sohn ag co kg ingelheim statement change group equity sharehol accrue thereof cur minority thereof cur millions eur der capital group capital rency effect equity interest rency effect group equity balance contribution withdrawal net income change balance contribution withdrawal net income change balance shareholder capital consist equity c h boehringer sohn ag co kg c h boehringer sohn grundstcksverwaltung gmbh co kg capital consist limited partner capital contribution shareholder personal taxis arise consolidated business activity show withdrawal accrue group capital item statement change equity value round millions eur disclose consolidated financial statement note boehringer ingelheim c h boehringer sohn ag co kg ingelheim note consolidated financial statement principle method general principle consolidate financial statement boehringer ingelheim financial year prepare accordance section german commercial code hgb line legal requirement prepare consolidated financial statement group management report section et seq hgb accordance section hgb consolidated financial statement consist consolidated balance sheet consolidated profit loss statement note consolidated financial statement cash flow statement statement change equity consolidated financial statement prepare euro accordance section conjunc tion section hgb improve clarity transparency consolidated financial statement individual item con solidate balance sheet consolidated profit loss statement combine item present explain separately note additional disclosure require individual item find note information company include consolidation parent company boehringer ingelheim group c h boehringer sohn ag co kg ingelheim boehringer ag ingelheim sole personally liable manage shareholder company c h boehringer sohn ag co kg c h boehringer sohn grundstcksverwaltung gmbh co kg general partner control c h boehringer sohn ag co kg boehringer ingelheim group consist total affiliated company germany abroad addi tion c h boehringer sohn ag co kg c h boehringer sohn grundstcksverwaltung gmbh co kg company c h boehringer sohn ag co kg directly indirectly hold majority voting right include consolidated financial statement consolidation rule accordance section hgb company include consolidation report ing year individually collectively insignificant term net asset financial position group earning total sale equity net income year company include consolidation account aggregated group financial statement total company classify associate accordance section hgb lack consolidated financial statement significance company ongoing restriction control term article association company consolidate accordance section hgb total number affiliate company fall compare previous year company found company liquidate previously affiliate company reclassify investment follow subsidiary exempt report disclosure obligation section hgb boehringer ingelheim gmbh ingelheim boehringer ingelheim europe gmbh ingelheim boehringer ingelheim vetmedica gmbh ingelheim boehringer ingelheim secura versicherungsvermittlung gmbh ingelheim boehringer ingelheim grundstcksgesellschaft mbh ingelheim boehringer ingelheim finanzierung gmbh ingelheim boehringer ingelheim rd beteiligung gmbh ingelheim boehringer ingelheim venture fund gmbh ingelheim follow subsidiary company exempt duty prepare disclose annual financial state ment management report accordance section b hgb c h boehringer sohn ag co kg ingelheim c h boehringer sohn grundstcksverwaltung gmbh co kg ingelheim boehringer ingelheim pharma gmbh co kg ingelheim c h boehringer selbstmedikation kg ingelheim boehringer ingelheim veterinary research center gmbh co kg hanover consolidation method inventory fix asset receivables liability income expense item transaction company include consolidation eliminate debt consolidation procedure accordance section hgb procedure eliminate intercompany profit accordance section hgb income expense consolidation procedure accordance section hgb revaluation method apply include subsidiary company consolidation time accordance section hgb company include consolidation time date company subsidiary carrying share hold parent company offset correspond equity subsidiary equity carry fair value asset liability prepay expense defer income special reserve include consolidated financial statement time consolidation remain balance offset capitalise goodwill consolidated financial statement note boehringer ingelheim currency translation asset liability result foreign currency transaction translate middle spot exchange rate balance sheet date realisation principle section conjunction section hgb historical cost convention section conjunction section hgb apply item remain term year consolidated financial statement financial statement foreign subsidiary domicile state outside eurozone denominate foreign currency convert euro accordance section hgb modify closing rate method modify closing date rate method asset liability item annual financial statement prepare foreign currency translate euro average spot exchange rate balance sheet date exception equity translate historical rate item include profit loss statement translate euro average rate result translation difference generally report consolidated equity reserve difference equity currency translation annual financial statement country hyperinflation expect foreign currency effect recognise currency translation accordance section hgb financial statement ii level improve true fair view consolidate financial statement exchange rate important currency group change follow report year basis eur yearend rate average annual rate dollar japanese yen pound sterling canadian dollar consolidated financial statement accounting policy fix asset acquire intangible asset tangible fix asset carry cost scheduled straightline amortisa tion depreciation determine consideration technical economic circumstance base follow useful life intangible asset year building year technical equipment machinery year equipment operate office equipment year straightline depreciation amortisation consolidated financial statement additional writedown record reflect impairment value asset consider permanently impair production cost include material labour manufacturing cost appropriate portion material labour overhead depreciation fix asset extent cause production capitalise intangible asset finite useful life goodwill firsttime consolidation shareholding usually amortise period year useful life year apply goodwill boehringer ingelheim korea ltd acquire past experience product sale market business condition boehringer ingelheim korea ltd indicate present true fair view financial asset essentially include shareholder right security loan carry low cost fair market value impair current asset prepaid expense inventory carry low cost fair market value raw material consumable supply capitalise low average acquisition price fair market value balance sheet date finish good work progress measure production cost basis individual calculation take account directly attributable cost material direct labour cost special direct cost appropriate share production material overhead cost depreciation good resale value lower purchase cost fair market value identifiable risk inventory asset arise aboveaverage storage period diminish marketability low replacement cost take account record appropriate valuation adjustment consolidate financial statement note boehringer ingelheim inventory value lossfree ie deduction expect sale price reflect cost incur receivables asset recognise cost allowance specific risk general credit risk lowinter noninterestbeare receivables term year discount security classify current asset include security recognise low cost quotedmarket price report date cash cash equivalent consist cash balance bank cheque recognise low cost fair market value defer charge prepaid expense record accordance section hgb include expense pay advance respect define period time balance sheet date defer charge record accordance section hgb include proceed represent income respect define period time balance sheet date negative difference acquisition company negative difference acquisition company recognise follow acquisition march august value net asset acquire exceed purchase price pay value negative difference acquisition company amount eur million january increase acquisition company acquire august eur million negative difference acquisition company amortise estimate period year release negative difference acquisition company eur million financial year eur million show oper ate income release consistent depreciation amortisation excess asset date acquisition consolidated financial statement group reserve group reserve include retain earning consolidate subsidiary prior year consoli dation entry affect earning relate previous year provision tax provision provision include uncertain liability expect loss executory contract carry require settle obligation base reasonable prudent commercial judgement ie include future cost price increase provision remain term year discount matchedterm average market interest rate seven year accord ance rckstellungsabzinsungsverordnung german regulation discount provision liability liability recognise settlement defer taxis calculate defer taxis arise temporary quasipermanent difference carry amount asset liability prepay expense defer charge commercial balance sheet carrying amount tax purpose tax loss carryforward amount result tax benefit expense time difference reverse measure tax rate specific respective consolidated company defer tax balance discount difference consolidation measure accordance section hgb measure company specific tax rate applicable time expect reversal difference defer tax asset loss carryforward take account likely year defer tax asset liability report setoff consolidated financial statement note boehringer ingelheim note consolidated balance sheet intangible asset acquire concession advance millions eur similar right goodwill payment total procurementmanufacture cost balance currency conversion difference change consolidate company addition disposal reclassification balance currency conversion difference change consolidate company addition disposal reclassification balance accumulate depreciation balance currency conversion difference change consolidate company addition writeup disposal reclassification balance currency conversion difference change consolidate company addition writeup disposal reclassification balance book value book value consolidate financial statement tangible asset advance technical facility payment land facility operating construction million eur building machine equipment progress total procurementmanufacture cost balance currency conversion difference change consolidate company addition disposal reclassification balance currency conversion difference change consolidate company addition disposal reclassification balance accumulate depreciation balance currency conversion difference change consolidate company addition writeup disposal reclassification balance currency conversion difference change consolidate company addition writeup disposal reclassification balance book value book value consolidate financial statement note boehringer ingelheim financial asset investment loan investment affiliate affiliate relate investment million eur company company company security loan total procurementmanufacture cost balance currency conversion difference change consolidate company addition disposal reclassification balance currency conversion difference change consolidate company addition disposal reclassification balance accumulate amortisation balance currency conversion difference change consolidate company addition writeup disposal reclassification balance currency conversion difference change consolidate company addition writeup disposal reclassification balance book value book value previous year loan item include loan shareholder consolidated financial statement inventory million eur raw material supply unfinished product finish product good resale advance payment supplier account receivable asset residual residual term term millions eur year year trade account receivable receivables affiliate company receivables related company asset asset item include receivables shareholder eur million previous year eur million receivable affiliate company previous year exclusively consist receivables loan receivables related company essentially consist trade account receivable provision million eur pension provision tax provision provision consolidated financial statement note boehringer ingelheim provision pension similar obligation provision pension similar obligation determine basis actuarial calculation project unit credit method take account future adjustment salarie pension addition local biometric datum eg germany mortality table g publish prof dr klaus heubeck pension obligation significant country calculate basis follow actu arial parameter december germany usa japan discount rate salary increase pension increase discount rate determine reference average market rate year maturity accordance german regulation discount provision november interest rate discount significant foreign pension obligation usa japan determine comparable param eter line german regulation discount provision november plan asset intend solely cover pension similar obligation unavailable cred itor plan asset define section hgb measure fair market value essentially derive stock market price offset underlie pension similar obligation fair market value plan asset balance sheet date eur million corresponding require settle offset pension obligation similar obligation eur million gain loss plan asset interest expense relate pension similar obligation offset accordance section hgb total eur million earning plan asset eur million interest expense relate pension similar obligation include financial result consolidated financial statement liability residual term residual term million eur year year year year bank loan account payable trade account payable advance payment account payable affiliate company account payable relate company liabilitie taxis eur million social security liability eur million previous year liability secure mortgage similar collateral right balance sheet date end year liability shareholder eur million previous year eur million present liability account payable affiliate company include loan amount eur million previous year eur million trade account payable amount eur million previous year eur million consolidated financial statement note boehringer ingelheim note consolidated profit loss statement structure consolidated profit loss statement base total cost format net sale business business segment million eur prescription medicine consumer health care animal health biopharmaceutical industrial customer sale geographic region millions eur europe germany americas usa asia australia africa japan operating income operating income include income currency translation eur million previous year eur million material cost million eur cost raw material supply good resale expenditure service consolidate financial statement personnel cost millions eur salary wage social benefit retirement benefits retirement benefit interest effect measurement provision pension similar obligation show separate item financial income average headcount production administration marketing sale research development apprentice amortisation intangible asset depreciation tangible asset amortisation intangible asset depreciation tangible fix asset include extraordinary writedown eur million previous year eur million operating expense operating expense include expense currency translation eur million previous year eur million addition operating expense include thirdparty service research development medicine marketing purpose administrative expense fee contribution commission rent freight expense repair carry party consolidate financial statement note boehringer ingelheim financial result million eur interest expense relate pension similar obligation provision interest expense similar expenditure interest expense similar expenditure amortisation loss disposal financial asset shortterm investment income investment security longterm loan interest income similar proceed hold income million eur writeoff financial asset income relate company disposal related company tax million eur income taxis defer taxis current income taxis essentially include corporation trade tax expense company include consolidation result conclusion profit transfer agreement significant german corporation include trade corporation tax group parent company c h boehringer sohn ag co kg january income taxis shareholder c h boehringer sohn ag co kg incur operating income report consolidated profit loss statement tax expense represent trade income tax affect company fully consolidated german partnership consolidate financial statement total defer tax asset amount eur million balance sheet date defer tax asset primarily relate difference carry amount recognise provision fix asset inventory defer tax liability eur million recognise primarily relate difference carry amount tangible asset inventory provision net income net income positively influence priorperiod operating income essentially reversal provision eur million previous year eur million negatively influence priorperiod operating expense eur million previous year eur million note cash flow statement cash flow statement show change cash cash equivalent cash longterm security investment classify current asset sell time boehringer ingelheim group result cash outflow report year accordance german accounting standard cash flow statement gas cash flow statement break accord cash flow operating activity cash flow invest financing activity change balance sheet item affiliate company include translate average rate year balance sheet cash cash equivalent carry closing rate effect exchange rate change cash cash equivalent show separately financial fund comprise financial asset remain maturity excess month date acquisition financial asset convert cash shortterm financial fund comprise follow item million eur cash cash equivalent security financial asset financial year interest eur million receive eur million previous year eur million interest pay tax payment amount eur million previous year eur million consolidated financial statement note boehringer ingelheim disclosure contingent liability millions eur liability guarantee bill cheque guarantee warranty grant security thirdparty liability risk utilisation individual contingent liability estimate follow risk utilisation guarantee liability bank affiliate company rate low account solid net asset financial position result operation subsidiary question financial commitment offbalance sheet transaction millions eur rental leasing obligation purchase commitment obligation rental lease agreement eur million previous year eur million eur million previous year eur million relate longterm rental agreement sub sidiarie include consolidation purpose lease agreement low capital commitment compare buy property absence resale risk risk arise term lease possible continue utilise property fully indication time financial commitment include future expense followup investment investment initiate future major repair balance sheet date purchase commitment include future cash flow effect investment total eur million previous year eur million derivative financial instrument valuation unit owe extensive international structure boehringer ingelheim group highly dependent development world currency interest rate hedge risk particularly emerge good service finance currency forwards option generally currency risk interest rate swap option interest rate risk consolidated financial statement use derivative financial instrument organisational process set internal guide line strict separation trading processing documentation control risk position regularly track analysed measure special groupwide financial report position enter periodically reevaluate monitor fair market value derivative financial instrument calculate standard market measurement method currency interest forwards net present value method currency interest option recognise option pricing model basis market datum available balance sheet date currency interest option recognise fair market value exceeding option premium pay receive derecognised maturity provision eur million recognise currency forward include hedge accounting negative fair market value currency balance sheet date line imparity principle positive fair market value currency recognise balance sheet date derivative financial instrument include hedge accounting valuation group follow nominal value market value millions eur foreign exchange forward contract extent requirement hedge account foreign currency forward exchange contract highly probable forecast transaction accordance section hgb meet foreign currency forward exchange contract recognise balance sheet line net hedge presentation method follow accounting policy apply recognition hedge accordance section hgb economic hedge account financial statement use valuation group valuation group recognise foreign currency base net highly probable forecast trans action currency forwards match forecast net cash flow term maturity nominal foreign currency macro hedge highly probable forecast transaction income outgoing payment plan sale purchase derive company plan expost analysis planning show plan transaction highly probable consolidated financial statement note boehringer ingelheim oppose change value hedge item hedge instrument fully offset critical term maturity nominal foreign currency match effective hedge assume prospectively retrospectively critical term match method exclusively measure prospective retrospective effectiveness hedge december hedge highly probable forecast net cash flow recognise follow january december net cash flow million eur fx forward contract millions eur nominal value nominal value market value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn gbp gbp gbp january december net cash flow million eur fx forward contract millions eur nominal value nominal value market value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn gbp gbp gbp january december net cash flow million eur fx forward contract millions eur nominal value nominal value market value usd usd usd jpy jpy jpy gbp gbp gbp consolidated financial statement january february net cash flow million eur fx forward contract millions eur nominal value nominal value market value usd usd usd jpy jpy jpy furthermore december hedge foreign currency receivable recognize follow receivables millions eur forward exchange contract millions eur nominal value nominal value market value rub rub rub pln pln pln hedge foreign currency risk correlate relative change exchange rate planning date realisation date forecast transaction currency appreciate depreciate euro foreign currency risk plus minus eur million hedge balance sheet date floatingrate loan amount eur million interest rate swap matching amount match maturity conclude hedge associate interest rate risk exclusively purpose convert floatingrate loan portion fix rate use hedge accounting micro hedge oppose change value hedge item hedge instrument fully offset match critical term interest rate swap include accrue interest negative fair market value eur million balance sheet date carrying equal defer accrue interest eur million report liability bank net hedge presentation method research development expense millions eur research development expense noncapitalise research development expense include item cost associate phase iv clinical study total auditor fee total fee charge group auditor financial year eur million eur million relate audits financial statement eur million assurance service eur million service consolidate financial statement note boehringer ingelheim auditor report audit consolidated financial state conduct audit consolidated financial ment prepare ch boehringer sohn ag statement accordance article hgb co kg ingelheim comprise balance handelsgesetzbuch german commercial code sheet income statement statement change german generally accept standard equity cash flow statement note audit financial statement promulgate consolidated financial statement institut der wirtschaftsprfer institute public group management report busi auditor germany idw standard ness year january december require plan perform audit preparation consolidated financial misstatement materially affect pre statement group management report entation net asset financial position accordance german commercial law result operation consolidate financial responsibility manage director statement accordance german principle manage corporate general partner responsi proper accounting group manage bility express opinion consolidated ment report detect reasonable assurance financial statement group management knowledge business activity eco report base audit nomic legal environment group expectation possible misstatement take account determination audit proce dure effectiveness accountingrelate internal control system evidence support ing disclosure consolidate financial statement group management report examine primarily test basis frame work audit audit include assess annual financial statement company include consolidation determination company include consolidation accounting consolidation principle significant estimate manage director manage corporate general partner evaluate overall presentation con solidated financial statement group man agement report believe audit provide reasonable basis opinion consolidated financial statement exception follow qualification audit lead reservation contrary article nos b hgb total remuneration grant member member board manage director member supervisory body pension provision recognize recognize member board manage director disclose note consolidated financial statement opinion base finding audit qualification mention consolidated financial statement comply legal requirement consolidate financial statement true fair view net asset financial position result operation group accordance german principle proper accounting group management report consistent consolidated financial statement comply legal requirement provide suitable view group position suitably present oppor tunitie risk future development frankfurt main february pricewaterhousecooper aktiengesellschaft wirtschaftsprfungsgesellschaft dr ulrich strk michael conrad wirtschaftsprfer wirtschaftsprfer german certify german certify public accountant public accountant product portfolio boehringer ingelheim pprroodduucctt ppoorrttffoolliioo p r u c po r f l e l e c n brand prescription medicine consumer health care animal health product portfolio brand prescription medicine boehringer ingelheim brand prescription medicine respiratory disease respiratory disease common chronic obstructive bronchial asthma pulmonary disease copd bronchial asthma bronchial asthma chronic inflammatory disorder prevalent chronic disease frequent airways inflammation accompany air cause morbidity premature death worldwide way hyperresponsiveness lead narrow airways recurrent episode wheeze breath idiopathic pulmonary fibrosis ipf rare disease lessness cough symptom occur particularly severely debilitate ultimately lethal night early hour morning know asthma trigger genetic envi copd ronmental factor eg allergen viral infection copd chronic disease lung cause cough unlike copd asthma occur early childhood ing excessive mucus production inflammation present adolescent adult asthma ultimately destroy lung tissue alveolus underestimate easy manage condition gas exchange affect lead limita patient asthma experience tion airflow cause shortness breath re symptom receive maintenance therapy put piratory symptom airflow limitation partially increase risk potentially lifethreatene reversible usually worsen time lead disa asthma exacerbation bility ultimately death symptom excess cough breathlessness main reason copd stressful patient lung emphysema chronic bronchitis main manifestation copd copd cause continuous damage lung result ing inhale pollutant primarily cigarette smoke factor need consider includ ing indoor outdoor air pollution course copd disease occur second half human life characterise accelerate loss lung function compare normal age occasional sud den worsen symptom function refer acute exacerbation lead downward spiral worsen symptom inactivity product portfolio indication brand name active ingredient chronic obstructive spiriva tiotropium bromide maintenance treatment patient pulmonary disease copd spiriva handihaler copd include chronic bronchitis spiriva respimat emphysema maintenance treat ment associate dyspnoea prevention exacerbation bronchial asthma spiriva respimat tiotropium bromide addon maintenance treatment adult patient asthma currently treat maintenance combination inhale corticosteroid spiriva respimat approve use asthma eu japan usa country label vary country refer local product information chronic obstructive spiolto respimat tiotropium bromide maintenance treatment airflow pulmonary disease copd stiolto respimat olodaterol obstruction patient chronic inspiolto respimat hydrochloride obstructive pulmonary disease copd chronic obstructive striverdi respimat olodaterol maintenance treatment patient pulmonary disease copd hyrochloride chronic obstructive pulmonary disease copd reversible bronchospasm combivent respimat ipratropium bromide combination short act anticho associate obstructive salbutamol sulphate linergic betaadrenergic airway disease management reversible bronchos pasm associate obstructive air way disease patient require bronchodilator chronic obstructive atrovent ipratropium bromide prevention treatment shortness pulmonary disease copd breath patients chronic chronic bronchitis obstructive pulmonary disease copd bronchial asthma mild moderate bronchial asthma adulthood childhood supple ment betaagonist case acute asthma chronic obstructive airway berodual ipratropium bromide fenoterol prevention treatment broncho disorder bronchodual hydrobromide spasm patient asthma duovent chronic obstructive pulmonary disease copd product portfolio brand prescription medicine boehringer ingelheim respiratory disease continue idiopathic pulmonary fibrosis ipf result individual ipf experience shortness ipf progressive lung disease associate markedly breath rest difficulty reduced life span affect people participate everyday physical activity worldwide ipf characterise progressive scar lung tissue loss lung function time acute ipf exacerbation define rapid deteriora development scarred tissue call fibrosis time tion symptom lung function day tissue thickens stiffen scar lung week event occur point course lose ability transfer oxygen disease presentation patient blood tream vital organ oxygen ipf risk acute ipf exacerbation cardiovascular disease cardiovascular disease lead cause death transient ischaemic attack tia similar stroke country increase prevalence minute hour usually result permanent neurological damage tia stroke precede stroke emergency medical care subsequent stroke rapidly develop loss brain function preventive treatment necessary reduce blood flow affect brain tissue ischaemia lack blood supply cause acute myocardial infarction thrombosis embolism bleed acute myocardial infarction heart attack result affect area brain unable function acute event occur thrombus clot suddenly damage quickly permanent untreated prevent blood flow area heart muscle stroke acute event require emergency diagnosis blood flow restore quickly affect section intervention worldwide stroke lead heart muscle permanently damage heart attack cause death longterm disability symptom lead cause death develop country product portfolio indication brand name active ingredient bronchial asthma berotec fenoterol hydrobromide symptomatic treatment acute asthma attack prophylaxis exerciseinduce asthma bronchiale symptomatic treatment allergic nonallergic asthma bronchiale condition reversible airway narrow eg chronic obstructive bronchitis bronchial asthma alesion epinastine hydrochloride prophylactic treatment patient allergic rhinitis flurinol bronchial asthma prophylaxis symp tomatic treatment allergic rhinitis idiopathic pulmonary fibrosis ofev nintedanib esylate treatment patient idiopathic ipf pulmonary fibrosis ipf indication brand name active ingredient h ypertension micardis telmisartan treatment hypertension cardiovascular morbidity micardisplus telmisartan hydrochlorothiazide reduction risk myocar mortality prevention micardi plus dial infarction heart attack stroke death cardiovascular cv cause micardishct patient year age old high comicardi risk develop major cv event unable ace inhibitor usa reduction cardiovascular morbidity patient manifest atherothrombotic cardiovascular dis ease history coronary heart disease stroke peripheral arterial disease patient type diabete mellitus document target organ damage eu hypertension twynsta telmisartan amlodipine treatment hypertension micamlo antihypertensive agent initial micardis amlo therapy patient likely need multi ple antihypertensive agent achieve micardis duo blood pressure goal usa addon therapy adult patient adequately control blood pre sure amlodipine replacement therapy adult patient receive tel misartan amlodipine separate tablet eu product portfolio brand prescription medicine boehringer ingelheim cardiovascular disease continue hypertension cardiovascular disease prevention venous thromboembolism hypertension refer high blood pressure patient undergo orthopaedic surgery consider chronic disease blood pressure chronically able risk develop deep vein thrombosis leg elevated hypertension major risk factor potentially fatal pulmonary embolism stroke heart attack heart failure chronic renal know venous thromboembolism vte thrombo failure embolic event recur chronic venous insuffi ciency andor pulmonary hypertension develop billion people worldwide affect hyper long term prevent vte event conse tension prevalence hypertension increase steadily quence patient receive kind thrombo age world population age preventive prophylaxis strategy term lifestyle change far fail swiftly increase incidence obesity prevalence treatment venous thromboembolism hypertension set increase vte umbrella term encompass deep vein thrombosis dvt pulmonary embolism pe dvt hypertension major risk factor cardiovascular process occur thrombus blood clot form morbidity mortality organ risk primarily deep vein commonly calf leg par heart main blood vessel brain kid tially completely block flow blood ney primary goal antihypertensive treatment major contributing factor dvt pathogenesis venous prevent cardiovascular event heart attack stasis thrombus grow portion break away stroke finally reduce cardiovascular mortality main clot travel circulatory system lung lodge blood clot artery cardiovascular disease cvd responsible nearly lung call pe vte disorder poten death worldwide number tially fatal consequence patient suffer medically relate cause death proper control treat vte require anticoagulant treatment secondary able risk factor disease vital prevention recurrent thromboembolic event prevention cardiovascular event reverse anticoagulation atrial fibrillation anticoagulant offer important benefit patient risk patient atrial fibrillation af high risk thromboembolic event rare develop blood clot cause disable stroke situation rapid reversal anticoagu clot travel brain af common lation medically necessary type arrhythmia associate hypercoagula ble state predispose stroke systemic embolism prevent effective chronic anticoagulation product portfolio indication brand name active ingredient secondary prevention aggrenox dipyridamole prevention stroke follow stroke transient ischaemic asasantin acetylsalicylic acid initial stroke transient ischaemic attack tia asasantin retard attack tia h ypertension catapresan clonidine treatment hypertension catapre hydrochloride clonidine catapressan cataprestts acute ischaemic stroke actilyse alteplase fibrinolytic treatment acute ischae acute myocardial infarction actilyse cathflo mic stroke acute myocardial infarction acute massive pulmonary acute massive pulmonary embolism embolism fibrinolytic treatment occlude cath catheter clearance eter thrombotic occlusion acute myocardial infarction metalyse tenecteplase fibrinolytic treatment acute myocar dial infarction hypertension motens lacidipine treatment hypertension stroke prevention atrial pradaxa dabigatran etexilate prevention stroke blood clot fibrillation pradaxar patient abnormal heart rhythm primary prevention venous prazaxa atrial fibrillation thromboembolic event orthopaedic surgery primary prevention venous thrombo treatment secondary embolic event vte adult prevention venous throm elective total hip knee replacement boembolic event surgery treatment deep vein thrombosis dvt pulmonary embolism pe secondary prevention recurrent dvt pe adult specific reversal pradaxa praxbind idarucizumab praxbind specific reversal agent dabigatran etexilate dabigatran indicate adult patient treat pradaxa dabigatran etexilate rapid reversal anti coaculant effect require emer gency surgeryurgent procedure lifethreatene uncontrolled bleed product portfolio brand prescription medicine boehringer ingelheim metabolic disease diabete type diabetes chronic progressive condition average decrease year approxi cause longterm complication control mately cent death people type diabete cause cardiovascular disease year million death worldwide link directly longterm effect diabete type diabetes addition cardiovascular disease complica common form account case tion diabete include nephropathy lead renal develop world affect million people failure potential risk dialysis retinopathy worldwide impose enormous burden health potential loss vision increase incidence stroke care system globally effective prevention cardiovascular disease peripheral neuropathy management estimate number case risk foot ulcer foot leg amputation reach million type diabete autonomic neuropathy cause gastrointestinal genitouri major risk factor cardiovascular disease life expectancy nary cardiovascular symptom sexual dysfunction people type diabete high cardiovascular risk product portfolio indication brand name active ingredient type diabete mellitus trajenta linagliptin treatment type diabete mellitus tradjenta improve glycaemic control adult trazenta monotherapy metformin tolerate contraindicated trayenta combination therapy type diabete mellitus jentadueto linagliptin metformin hydrochloride treatment type diabete mellitus trayenta duo improve glycaemic control adult trajenta duo treatment metformin lead sufficient control trajentamet patient treat trajenta linagliptin metformin type diabete mellitus jardiance empagliflozin treatment type diabete mellitus jardianz improve glycaemic control adult monotherapy diet exercise provide adequate glycaemic control metformin consider inappropriate intoler ance combination therapy type diabete mellitus synjardy empagliflozin treatment type diabete mellitus metformin improve glycaemic control adult hydrochloride treatment metformin lead sufficient control patient treat jardiance empagliflozin metformin type diabete mellitus glyxambi empagliflozin linagliptin treatment type diabete mellitus improve glycaemic control adult treatment empagliflozin linagliptin appropriate product portfolio brand prescription medicine boehringer ingelheim oncology cancer threat global health estimate symptom unspecific year million new case cancer diagnose world appear late diagnosis advanced stage disease wide million people die cancer result dismal prognosis lung common diagnose cancer type lung cancer cancer patient survive year follow breast cancer colorectal cancer diagnosis lung cancer lung cancer disease dif lung cancer refer malignant abnormal cell growth ferent subtype small cell lung cancer sclc inside lung tissue form cluster tumour nonsmall cell lung cancer nsclc differ common cancer estimate million ent molecular genetic aberration mutation present new case year worldwide smoking pri tumour identify focus molecu mary cause disease contribute lar change specific respective subtype case recently incidence lung cancer lung cancer target therapy effec non smoker woman increase lung tive treatment show survival benefit cancer poor prognosis million death time harmful normal cell year represent cancer death lung cancer reduce effect disease central nervous system mental neurological disease depression dementia depression sleep disorder parkinson disease significantly impact patient primary symptom result lack neuro family substantial burden society transmitter dopamine distinct area human brain parkinson disease restless leg syndrome rls parkinson disease pd degenerative disorder restless leg syndrome rls common neurological central nervous system patient usually notice motor disorder characterise uncontrollable urge symptom like hand tremor shake sign leg primarily occur evening night disease progress eventually include shak hour usually accompany unpleasant ing arm legs head motor symptom time painful sensation leg disturb develop time include stiffness result sleep result daytime tiredness sleepiness loss facial expression gradual slow loss sensation feel deep leg describe motion freeze patient creep crawl ache suffer nonmotor symptom associate pd product portfolio indication brand name active ingredient nonsmall cell lung cancer giotrif afatinib treatment patient nsclc gilotrif metastatic nonsmall cell lung cancer nsclc tumor activate epidermal growth factor receptor egfr mutations nonsmall cell lung cancer vargatef nintedanib combination therapy docetaxel nsclc treatment adult patient locally advanced metastatic locally nonsmall cell lung cancer nsclc adenocarcinoma tumour histology firstline chemotherapy indication brand name active ingredient parkinson disease pd sifrol pramipexole symptomatic treatment idiopathic restless leg syndrome rls mirapex parkinson disease mirapexin monotherapy combination levodopa symptomatic treatment pexola idiopathic moderate severe restless leg syndrome sleep disorder lendormin brotizolam shortterm treatment disorder lindormin initiate maintain sleep insomnia require pharmacological intervention product portfolio brand prescription medicine boehringer ingelheim infectious disease hiv infectionaid acquire immune deficiency syndrome aid set symptom infection result damage human immune system cause human immu nodeficiency virus hiv untreated infection hiv progressively reduce effectiveness immune system leave individual susceptible opportunistic infection tumour baby infect mother risk get virus pregnancy childbirth breastfeed product portfolio indication brand name active ingredient hivaid viramune nevirapine combination therapy hiv viramune xr infection country prevention mothertochild trans mission hiv pregnant woman take antiretroviral therapy time labour prolong release tablet oncedaily dose combination therapy hivaids aptivus tipranavir indicate combination antiretroviral treatment hivinfecte patient coadministere mg ritona vir treatmentexperience infect hiv strain resistant protease inhibitor product portfolio consumer health care boehringer ingelheim consumer health care cough cold mucosolvan ambroxol bisolvon bromhexine dextromethorphan symptomatic treatment indicate secretolytic therapy broncho irritable nonproductive cough market vari pulmonary disease associate abnormal mucus ety tradename specific country central secretion impaired mucus transport cough suppressant effect aim normalize cough threshold cough common symptom clinical impor tance frequent reason consulting doctor mucoviral bisolviral antiviral nasal spray visit pharmacy clinical symptom cough launch spray contain iotacarra expectoration lead development drug geenan extract natural red seaweed affect respiratory mucus ie mucoactive agent apply nasally iotacarrageenan act like protective layer physically inhibit infection nasal epithe mucosolvan promote mucus clearance facilitate lial cell cold virus virus dock expectoration ease productive cough allow specific receptor cell surface clinical trial patient breathe freely deeply available use mucoviralbisolviral show different product form formulation typically reduce viral load patient nasal secretion base active ingredient ambroxol relieve symptom cold ambroxol mucoactive drug property boxagrippal launch germany follow include secretolytic secretomotoric action successful switch prescription overthecounter restore physiological clearance mechanism otc medicine status cold remedy combine respiratory tract play important role bodys antiinflammatory pain reliever nsaid ibuprofen natural defence mechanism ambroxol stimulate syn oral decongestant pseudoephedrine hydrochloride thesis release surfactant type ii pneumocyte treat troublesome symptom cold block nose sinus combination headache fever bisolvon bromhexine market coldrelated pain bromhexine contain formulation bisolvon show increase proportion active ingredient tramazoline treatment bronchial secretion make easily block nose available number country expectorate bromhexine enhance mucus trans range brand name include rhinospray port reduce mucus viscosity activate muconasal lasolvan rhino ciliated epithelium product portfolio indication brand name active ingredient acute chronic broncho mucosolvan ambroxol secretolytic therapy acute chronic pulmonary disease mucosan bronchopulmonary disease associate surbronc abnormal mucus secretion impaired mucus transport lasolvan mucopect acute chronic broncho bisolvon bromhexine secretolytic therapy acute chronic pulmonary disease bronchopulmonary disease associate abnormal mucus secretion impair mucus transport irritable cough silomat dmp dextromethorphan symptomatic treatment irritable bisoltussin nonproductive cough bisolvon dry bisolsek bisolvon antitusivo mugotussol mucotussin surbronc toux sche common cold mucoviral iotacarrageenan antiviral treatment common cold bisolviral sustain moisturi surbroncviral sation nasal mucosa common cold boxagrippal ibuprofen symptomatic treatment nasal conge bisolfren pseudoephedrine tion combination headache fever nasal congestion rhinospray tramazoline relief swell nasal rhinospray plus mucosa ie nasal congestion associated muconasal common cold hay fever facilitate drainage secretion lasolvan rhino sinusitis otitis medium lasorin spraytish rinogutt product portfolio consumer health care boehringer ingelheim sore throat sore throat product range offer solution local anaesthetic effect describe sore throat pain hoarseness late efficacy safety mucoangin show recent clinical trial mucoangin main brand tratment sore throat available lozenge variety flavour mucoangin lysopaine spray format mucoangin ambroxol indicate pain relief lysopaine cetylpyridinium lysozyme combine acute sore throat pain sore throat hallmark know antiseptic enzyme play key role acute pharyngitis usually cause viral infection bodys natural immune system antibacterial formula infection rule selflimite patient indicate sore throat low intensity fever mally recover day bothersome patient continuous pain throat voxlysopainelizivoz lozenge double layer maximise swallow main goal treat natural iceland moss alum offer double ment reduce pain effect soothe mucous membrane throat calm hoarseness act like barrier addition secretolytic activity ambroxol potent protect throat attack outside inhibitor neuronal sodium channel show product portfolio indication brand name active ingredient sore throat mucoangin ambroxol pain relief acute sore throat lysopadol lysopain dol isodinemint lizipadol zerinol gola sore throat lysopaine cetylpyridinium lysozyme local adjuvant treatment sore throat low intensity fever adult child year old hoarseness voxlysopaine iceland moss alum help reduce hoarseness improve lizivoz strength voice lysopain voice zerinolvox product portfolio consumer health care boehringer ingelheim pain boehringer ingelheim overthecounter otc pain port component suppress pain synergistically folio consist number lead brand different interaction painr elated molecular mecha country world brand eve lead nism result thomapyrin classic offer fast analgaesic japanese otc market eve offer product superior efficacy compare single component base innovative ibuprofen formulation prove current clinical study specifically tailor need female consumer lead product eve eve quick eve ex reason triple combination recommend innovative fast release galenical form national international medical society develop boehringer ingelheim scientist japan choice acute treatment tensiontype headache migraine thomapyrin position expert treat brazil anador general pain brand moderate ment headache line extension vailable severe pain lead position market thomapyrin classic headache thomapyrin inten metamizole principle active ingredient anador siv strong headache brand thomapyrin comprise product brand finalgon nonivamid nicoboxil treatment acute pain mild moderate intensity topical cream joint muscle pain primarily available germanspeake country thomapyrin classic core product thomapyrin brand compose triple combi nation acetylsalicylic acid paracetamol caffeine product portfolio indication brand name active ingredient pain eve ibuprofen adult old year reduc eve quick allylisopropylacetylurea dehydrate tion fever temporary relief mild eve ex caffeine magnesium oxide moderate ache pain associate headache menstrual pain body pain available japan eve quick pain anador metamizole moderate severe acute pain lisalgil sodiummetamizole magnesium include colicky pain tumor pain nolotil high fever respond general therapeutic measure prodolina available brazil pain thomapyrin classic acetylsalicylic acid adult adolescent old thomapyrin paracetamol caffeine year acute treatment mild intensiv moderate headache migraine attack aura treat ment tensiontype headache available germany pain lonarid paracetamol codeine phosphate moderate severe pain adult lonarid n paracetamol codeine phosphate adolescent aged year old prontalgine caffeine adult adolescent year age old symptomatic treat ment moderate severe pain respond peripheral analgesic available france pain finalgon nonivamid nicoboxil stimulate blood flow skin treat joint muscle complaint product portfolio consumer health care boehringer ingelheim gastrointestinal disease gastrointestinal portfolio offer brand buscopan prefer choice reliable relief dulcolax surulac laxoberal guttalax pain discomfort abdominal cramp buscopan vaprino heartburn brand unique proven formula gently relax cramped mus zantac gastol cle digestive tract act pain occurs relieve spasm cause abdominal constipation common problem dulcolax pain active ingredient buscopan hyoscine lead overthecounter otc laxative remedy con butylbromide derive natural substance stipation relief worldwide extract duboisia plant dulcolax tablet special enteric comfort coating buscopan offer line product mono vari ensure active ingredient dulcolax ant different combination analgesic par tablet bisacodyl take need act acetamol ibuprofen metamizoldipyrone colon stimulate natural movement bowel different format tablet drop suppository syrup provide gentle predictable relief hour solution intravenous injection tablet take go bed provide relief morning umbrella brand buscopan offer buscofem menstrual pain relief product dulcolax range include dulcoease dulcoenema dulcosoft dulcogas extend gastrointestinal portfolio vaprino selfmedication product diarrhoea surulac constipation brand japan consum active ingredient racecadotril effective form er offer surulac laxative tablet laxoberal acute diarrhoea reduce excessive secretion guttalax brand offer consumer consti gut change gastrointestinal transit time pation relief flexible dosage format drop motility thank new way action vaprino ena ble fast relief diarrhoea block bowel abdominal cramping pain discomfort common ailment approximately person worldwide zantac brand ranitidine own usa suffer regular basis boehringer ingelheim represent lead heartburn brand market product portfolio indication brand name active ingredient constipation dulcolax bisacodyl laxative use patient suffer surulac bisacodyl sennoside constipation preparation diagnostic procedure pre postoperative treatment condi tion require defecation facili tat constipation laxoberal sodium picosulphate laxative use case constipation laxoberon condition require defeca guttalax tion facilitate dulcolax np constipation dulcosoft macrogol laxative symptomatic treat ment constipation allow soften hard fece facilitate disposal gas bloat dulcogas simethicone fastacting granule relieve gas bloat prevent flatulence abdominal pain buscopan hyoscine butylbromide treatment relief abdominal buscapina hyoscine butylbromide paracetamol cramp pain discomfort buscopan plus buscapina plus acute diarrhoea vaprino racecadotril treatment symptom acute diar rhoea adult heartburn zantac ranitidine fast last relief heartburn available usa product portfolio consumer health care boehringer ingelheim vitamin supplements pharmaton multivitamin brand develop sup pharmaton contain select blend vitamin port physical mental range prod mineral trace element plus omega main indi uct develop meet need different tar cation help maintain cardiovascular health audience adult adult child help cover daily need vitamin mineral omega fatty acid act complementary daily pharmaton range product adult contain nutrition select blend vitamin mineral trace element plus standardised ginseng extract g main pharmaton kiddi range product design target indication exhaustion tiredness decrease child contain essential amino acid lysine plus concentration mental alertness case select vitamin mineral important deficient nutrition loss appetite debility illness period growth support healthy physical convalescence numerous clinical study show mental development recommend regular intake pharmaton positive effect preventive treatment vitamin deficiency mental physical performance wellbee product portfolio indication brand name active ingredient tiredness decrease concen pharmaton ginseng extract improve general wellbeing tration case deficient pharmaton vitality vitamin mineral support physical mental energy nutrition loss appetite pharmaton geriavit trace element debility illness geriatric pharmaton convalescence gericomplex pharmaton complex pharmaton fizzi pharmaton active life help maintain cardiovas pharmaton vitamin mineral improve general wellbee cular health help cover pharmaton plus omega fatty acid support physical mental energy ing daily need vita min mineral omega fatty acid act comple mentary daily nutrition increase demand vita pharmaton kiddi vitamin cover increase demand vita min childhood minerals min mineral amino acids espe amino acid cially period growth pre ventive treatment case vitamin deficiency eg case restrict inadequate diet loss appetite sub sequent illness infection surgery convalescence prophylaxis iron folic pharmaton matruelle vitamin mineral woman pregnancy acid deficiency preg trace element prevent deficiency symptom nancy omega fatty acid cover increase need vita docosahexaenoic min mineral trace element dha acid dha provide protection embryonal neural tube disease foetus prophylaxis iron folic acid anae mia pregnancy breastfeed product portfolio consumer health care boehringer ingelheim leg vein health brand antistax boehringer ngelheim symptoms antistax help fluid flow market broad range product develop pre small venous vessel venule surround vention treatment symptom attributable chronic tissue normal level stand sit venous insufficiency common symptom long time venous insufficiency observable consumer varicose vein oedema low leg heavy tired leg sensation red vine leaf extract active ingredient antistax tension tingling cramp pain antistax tablet product antiinflammatory effect work scientifically prove help maintain healthy leg vein endothelium inside venule seal circulation inside reduce swell sensation pain heaviness heavy aching tired leg occur long period stand sit increase end day product available antistax range include ntistax summer outdoor temperature rise tablet antistax vein creme antistax cool antistax tablet offer effective treatment describe gel leg urological disease benign prostate hyperplasia bph refer enlargement prostate middleage elderly man lead low urinary tract symptom luts fre quent nighttime urination urge urinate hour weak flow feel unfinished urinating product portfolio indication brand name active ingredient chronic venous insufficiency antistax red vine leaf extract prevention treatment symptom chronic venous insufficiency varicose veins leg oedema painful swollen leg tingle leg tired heavy leg heavy tired leg antistax red vine leaf extract relief revitalize tired heavy vein cream leg heavy tired leg antistax red vine leaf extract menthol cool refresh heavy tired leg fresh leg gel peppermint oil hydrate skin indication brand name active ingredient benign prostate hyperplasia flomax relief mr tamsulosin treatment low urinary tract symp bph tom lut common condition call benign prostate hyperplasia bph available uk overthecounter otc medication product portfolio animal health boehringer ingelheim foodproduce animal swine infectious respiratory disease ingelvac mycoflex license active immunisa ingelvac circoflex singledose piglet vaccine tion pig enzootic pneumonia ep single control porcine circovirus disease pcvd dose regimen advance adjuvant system vaccine provide significant reduction mortality provide longlaste effective protection prove acute phase pcvd improve growth rate highchallenge situation chronic phase disease ingelvac circoflex protect minimal systemic adverse reaction injec infectious enteric disease tion site swelling pregnancy enterisol ileitis vaccine lactation ingelvac prrs product license ileitis cause lawsonia intracellularis license active immunisation respiratory reproduc improve weight gain reduce growth variability tive form porcine reproductive respiratory syn associate disease enterisol ileitis help drome prrs reduce total antimicrobial use pork production foodproducing animal poultry volvac umbrella brand boehringer ingelheim viral bacterial disease like avian animal health poultry vaccine range consist influenza infectious bronchitis newcastle disease infec wide range live inactivate vaccine broiler tious bursal disease egg drop syndrome avian coryza layer vaccine provide protection bird product portfolio indicat ion brand name active ingredient infectious respiratory ingelvac circoflex recombinant vaccine active immunisation pig isease porcine circovirus age week porcine type pcv circovirus type reduce mortality clini cal sign include weight loss lesion lymphoid tissue asso ciate porcine circovirus disease pcvd addition vaccination show reduce pcv nasal shed viral load blood lymphoid tissue duration viraemia infectious respiratory ingelvac prrs mlv attenuate live vaccine prrs virus depend product active isease ingelvac prrsflex eu type prrs mlv immunisation pig age reprocyc type prrsflex eu porcine reproductive reprocyc respiratory syndrome virus prrsv infectious respiratory ingelvac mycoflex inactivate vaccine active immunisation pig isease mycoplasma age week reduce lung hyopneumoniae lesion follow infection myco plasma hyopneumoniae infectious enteric disease enterisol ileitis attenuate live vaccine lawsonia active immunisation pig intracellularis age week intestinal lesion cause lawsonia intracellularis infection reduce growth variabil ity loss weight gain associate disease indicat ion brand name active ingredient viral bacterial volvac polyvalent attenuate live vaccination healthy chicken disease poultry inactivated vaccine disease cause include contain antigen antigen prevention vaccination avian common disease broiler chicken influenza newcastle disease responsible loss egg disease avian coryza egg production layer drop syndrome infectious bronchitis infectious bursal disease bacterium anatis product portfolio animal health boehringer ingelheim foodproduce animal cattle mastitis mastitis inflammation udder dairy cattle mainly cause bacterial infection prevention treatment mastitis animal key produce healthy milk minimise symptom associate clinical situation mamyzin effective injectable antimicrobial treatment acute masti tis ubrolexin today product treatment acute bacterial mastitis ubrostar tomorrow prevent mastitis dry ingoff dairy cattle end lactation period product portfolio indicat ion brand name active ingredient astitis mamyzin penethamate hydroiodide bovine mastitis cause penicillin sensitive organism astitis ubrostar penethamate hydroiodide framyce treatment subclinical mastitis benestermycin tin sulphate benethamine penicillin drying prevention new mamyzin secado bacterial infection udder dry period dairy cow cause bacteria susceptible penicillin framycetin astitis ubrolexin cefalexin kanamycin combination treatment clinical mastitis lactate dairy cow bacteria susceptible combination cefalexin kana mycin astitis today cephapirin sodium treatment clinical mastitis lactate cefalak dairy cow uscanada astitis tomorrow cephapirin benzathine treatment subclinical mastitis cefadri dry prevention new bacterial infection udder dry period dairy cow uscan ada intramammary infusion dry cow product portfolio animal health boehringer ingelheim foodproduce animal cattle continue pain inflammatory disorder infectious disease metacam nonsteroidal antiinflammatory drug pyramid family vaccine provide broad nsaid address need maintain profita coverage respiratory reproductive disease bility concern animal welfare animal pro range consist antigen combination duction longacte nature outstanding efficacy control inflammatory symptom metacam bovine viral diarrhoea virus bvdv major help minimise loss inflammation maintain economically relevant cattle pathogen worldwide profitability time metacam e ffectively distribution disease cause bvdv result mark control pain support restoration wellbee production loss dairy beef herd bovela farm animal use metacam c onvenient vaccine design reduce clinical sign inflict minimal stress animal lowvolume typical bvd prevent birth socalle oneshot dosage sistently infect animal cause transplacental infec tion bvdv vaccination bovela expect metacam license adjunctive therapy treat provide protection herd disease ment mastitis lactate cow country circulation virus indicate use calf affect diarrhoea cattle suffer respiratory disease product portfolio indicat ion brand name active ingredient pain inflammatory metacam meloxicam cattle metacam isorder appropriate antibiotic therapy reduce clinical sign disease acute respiratory infection diarrhoea combination oral rehydration therapy reduce clinical sign disease calf week age young nonlactat ing cattle relief postoperative pain follow dehorn calf supportive therapy treatment acute masti tis combination antibiotic cattle infectious disease pyramid multivalent vaccine combi vaccination healthy dairy beef respiratory reproductive presponse nation include modify live cattle aid prevention disease disease cattle virus bovine viral diarrhoea bvd cause include antigen type infectious bovine canada rhinotracheitis ibr parainflu enza pi bovine respiratory syncytial virus brsv bacteria pasteurella multocida mannheimia haemolytica l canicola l grippoty phosa l hardjo l icterohaemmor rhagiae l pomona bovine viral diarrhoea bvd bovela modify live bvdv strain bovela protect cattle modify live bvdv strain bvd viral infection bovine viral diarrhoea virus product portfolio animal health boehringer ingelheim companion animal horse main horse product focus therapeutic area vetera vaccine formulate utilise ultrafil respiratory disease lameness colic hormonal purification technology remove extraneous pro disorder tein allow horse immune system focus relevant antigen prascend indicate treatment pituitary par intermedia dysfunction ppid know respiratory segment product available global equine cushing disease prascend substitute level ventipulmin equisolon product lack dopamine pituitary par intermedia clinical license treatment respiratory disease include airway sign hypertrichiosis laminitis change body con obstruction horse wheeze cough difficulty formation lack performance treatment breathing bronchospasm andor mucus accumulation prascend lifelong ventipulmin equisolon adjunctive therapy chronic obstructive pulmonary disease vetera vaccine vaccine portfolio copd acute subacute chronic respiratory allergic include ultiple convenient combination disease pro condition tection horse young month age vaccine protect infectious organism include influenza herpe west nile virus tetanus enable customise pro tection horse limited needle injection product portfolio indicat ion brand name active ingredient pituitary par intermedia prascend pergolide mesylate symptomatic treatment clinical sign dysfunction ppid asso ciate pituitary par intermedia dysfunction ppid know equine cushing disease way combination vetera eastern western venezuelan vaccination healthy horse vaccine common encephalomyelitis tetanus west aid prevention disease cause disease horse nile virus equine include antigen canada herpes virus equine influenza viruse acute chronic obstructive ventipulmin clenbuterol treatment respiratory disease horse respiratory disease airway obstruction bron chospasm andor accumulation mucus contribute factor improve mucociliary clearance desirable recurrent airway obstruction equisolon prednisolone treatment recurrent airway rao heave obstruction rao heave horse combination environmental measure product portfolio animal health boehringer ingelheim companion animal small animal main small animal product address major chronic prozinc aqueous protamine zinc pzi suspension disease heart failure kidney disease epilepsy oste recombinant human insulin reduce oarthritis hyperglycaemia cat diabete mellitus new class heart treatment term semintra angiotensin ii antagonist inodilator vetmedin show significantly approve reduction proteinuria associate improve clinical sign extend life expectancy dog chronic kidney disease ckd cat semintra congestive heart failure originate dilate decrease mean arterial blood pressure proteinuria cardiomyopathy valvular insufficiency mitral andor available oral solution tricuspid regurgitation vetmedin work complementary mode action open blood pexion alternative treatment canine epilepsy vessel take blood away heart active substance imepitoin primarily inhibit lower pressure heart reduce seizure potentiation gabaareceptormediate work heart pump blood dog inhibitory effect neuron pexion approve body time vetmedin direct effect reduction generalise seizure idiopathic epi heart muscle helping beat strong pump lepsy potential safety benefit exist blood efficiently standard treatment metacam nonsteroidal antiinflammatory drug duramune bronchishield vaccine design nsaid available oral suspension tablet aid prevention wide spectrum common injectable solution dog oral suspen infectious disease dog disease sion injectable solution cat dog indica case fatal effective preven tion include alleviation inflammation pain tion include appropriate vaccination reduce impact acute chronic musculoskeletal disorder disease dog reduction postoperative pain follow surgery cat indication include alleviation inflammation pain acute chronic musculo skeletal disorder alleviation mild moderate postoperative pain follow surgical proce dure variety formulation offer veterinarian owner flexibility use formulation prefer manage level inflammation pain associate license indication product portfolio indicat ion brand name active ingredient congestive heart failure vetmedin pimobendan treatment canine congestive heart failure originate dilatative cardio myophathy valvular insufficiency mitral andor tricuspid regurgitation treatment dilate cardiomyopa thy preclinical stage asymptomatic increase leave ventricular endsystolic enddiastolic diameter doberman pinscher follow echo cardiographic diagnosis cardiac disease pain inflammatory metacam meloxicam dog metacam reduce disease postoperative pain inflammation follow orthopaedic eg fracture oper ation soft tissue surgery cat metacam reduce postoperative pain inflammation ovariohysterectomy spay opera tion orthopaedic minor soft tissue surgery alleviation pain inflammation acute chronic musculoskeletal disorder dog cat feline diabete mellitus prozinc protamine zinc reduction hyperglycaemia recombinant hyperglycaemiaassociated clinical sign human insulin cat diabete mellitus feline chronic kidney disease semintra telmisartan reduction proteinuria associated chronic kidney disease ckd cat canine idiopathic epilepsy pexion imepitoin reduction frequency generalise seizure idiopathic epilepsy dog careful evaluation alternative treatment option canine infectious disease duramune inactivated attenuate vaccine vaccination healthy dog aid bronchishield canine distemper canine prevention disease cause adenovirus type coronavirus include antigen canada parainfluenzavirus parvovirus australia borrelia burgdorferi leptospira canicolagrippotyphosa icterohaemor rhagiae pomona bordetella bronchi septica comparison balance sheet boehringer ingelheim c h boehringer sohn ag co kg ingelheim comparison balance sheet million eur asset december intangible asset tangible asset financial asset fix asset inventory account receivable incl defer charge defer taxis liquid fund current asset incl deffered charge defer taxis total asset liability equity december shareholder capital reserve incl currency conversion difference net income total equity minority interest group equity negative difference acquisition company provision incl defer taxis liability incl defer charge total liability incl defer taxis defer charge total liability equity summary select financial datum net sale operating income operating income net sale income taxis income taxis net sale return shareholder equity equity ratio cash flow financial fund personnel cost personnel cost net sale average number employee research development cost r net sale investment tangible asset depreciation tangible asset imprint asset december intangible asset tangible asset financial asset boehringer ingelheim gmbh binger strae fix asset ingelheim inventory germany account receivable incl defer charge defer taxis telephone fax liquid fund current asset incl deffered charge defer taxis contact total asset corporate division communication email webmasterboehringeringelheimcom internet wwwboehringeringelheimcom liabilitie equity december shareholder capital issue reserve incl currency conversion difference boehringer ingelheim gmbh net income concept design layout total equity mpm corporate communication solution mainz minority interest wwwmpmde group equity negative difference acquisition company photo provision incl defer taxis dieth schrder fotografie p liabilities incl defer charge print total liability incl defer taxis defer charge neue sddeutsche verlagsdruckerei gmbh ulm total liability equity copyright boehringer ingelheim gmbh summary select financial datum right reserve annual report net sale reproduce transmit form mean operate income electronic photocopy permission write boehringer ingelheim gmbh figure party operating income net sale annual report base datum available time income taxis financial statement draw income taxis net sale return shareholder equity equity ratio cash flow financial fund personnel cost personnel cost net sale average number employee research development cost r net sale investment tangible asset depreciation tangible asset